| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts Index
|
|
|
2006
|
9 |
3 |
p. A180-A186
nvt p.
|
artikel
|
| 2 |
Abstracts Index
|
|
|
2006
|
9 |
3 |
p. A180-A186
|
artikel
|
| 3 |
AC3 DETERMINANTS OF NON-COMPLIANCE WITH BISPHOSPHONATE THERAPY IN WOMEN WITH POST-MENOPAUSAL OSTEOPOROSIS
|
Penning-van Beest, FJ
|
|
2006
|
9 |
3 |
p. A1-A2
nvt p.
|
artikel
|
| 4 |
AC4 OCCURRENCE OF THROMBOCYTOPENIA AFTER ORTHOPEDIC SURGERIES IN PATIENTS TREATED WITH FONDAPARINUX, DALTEPARIN, ENOXAPARIN OR UNFRACTIONATED HEPARIN
|
Sarnes, M
|
|
2006
|
9 |
3 |
p. A2-
1 p.
|
artikel
|
| 5 |
AC2 THE PREVALENCE OF SUBJECTIVELY EXPERIENCED ADVERSE DRUG REACTIONS. A NATIONWIDE SURVEY IN SWEDEN
|
Isacson, D
|
|
2006
|
9 |
3 |
p. A1-
1 p.
|
artikel
|
| 6 |
AC1 USING TABLET PCS FOR SMOKING HAZARDS EDUCATION IN A METHADONE CLINIC
|
Finkelstein, J
|
|
2006
|
9 |
3 |
p. A1-
1 p.
|
artikel
|
| 7 |
Bringing Health Economic Modeling to the 21st Century
|
Eddy, David
|
|
2006
|
9 |
3 |
p. 168-178
11 p.
|
artikel
|
| 8 |
Bringing Health Economic Modeling to the 21st Century
|
Eddy, David
|
|
2006
|
9 |
3 |
p. 168-178
|
artikel
|
| 9 |
CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA
|
Blackhouse, G
|
|
2006
|
9 |
3 |
p. A8-
1 p.
|
artikel
|
| 10 |
CE1 PHARMACOECONOMIC EVALUATION OF SINGLE DOSE AZITHROMYCIN EXTENDED RELEASE (AZ-ER) FORTHE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)
|
Sorensen, SV
|
|
2006
|
9 |
3 |
p. A7-
1 p.
|
artikel
|
| 11 |
CE3 SHORT-TERM COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE
|
Earnshaw, SR
|
|
2006
|
9 |
3 |
p. A8-
1 p.
|
artikel
|
| 12 |
CE2 THE COST-EFFECTIVENESS OF ZEMPLAR IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2006
|
9 |
3 |
p. A7-A8
nvt p.
|
artikel
|
| 13 |
CN3 COLONOSCOPY PROCEDURE RATES AMONG PRIVATE-PAY PATIENTS INCREASED SUBSTANTIALLY BETWEEN 2000 AND 2004
|
Amorosi, SL
|
|
2006
|
9 |
3 |
p. A18-A19
nvt p.
|
artikel
|
| 14 |
CN4 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING
|
Duh, M
|
|
2006
|
9 |
3 |
p. A19-
1 p.
|
artikel
|
| 15 |
CN1 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS: A PRIVATE PAYER PERSPECTIVE
|
Pelletier, EM
|
|
2006
|
9 |
3 |
p. A18-
1 p.
|
artikel
|
| 16 |
CN2 MAMMOGRAPHY SCREENING USE AMONG MEDICARE BENEFICIARIES AGE 65 OR OLDER
|
Zuckerman, IH
|
|
2006
|
9 |
3 |
p. A18-
1 p.
|
artikel
|
| 17 |
Contributed Podium Presentations
|
|
|
2006
|
9 |
3 |
p. A1-A23
|
artikel
|
| 18 |
Contributed Poster Presentations
|
|
|
2006
|
9 |
3 |
p. A24-A173
|
artikel
|
| 19 |
Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden
|
Jönsson, Linus
|
|
2006
|
9 |
3 |
p. 193-198
6 p.
|
artikel
|
| 20 |
Cost of Hypoglycemia in Patients with Type 2 Diabetes in Sweden
|
Jönsson, Linus
|
|
2006
|
9 |
3 |
p. 193-198
|
artikel
|
| 21 |
CS2 ECONOMIC BURDEN OF WORK LOSS AMONG SUFFERERS OF LYMPHATIC FILARIASIS: AN ERADICABLE GLOBAL HEALTH PROBLEM
|
Singh, M
|
|
2006
|
9 |
3 |
p. A2-A3
nvt p.
|
artikel
|
| 22 |
CS4 FREQUENCY AND COST OF DISABILITY AMONG EMPLOYED INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
Darkow, T
|
|
2006
|
9 |
3 |
p. A3-
1 p.
|
artikel
|
| 23 |
CS1 THE ECONOMIC AND HEALTH CONSEQUENCES IN SWEDEN OF MANAGING BRADYCARDIA WITH ADAPTA® COMPARED TO A STANDARD DUAL CHAMBER PACEMAKER
|
Deniz, HB
|
|
2006
|
9 |
3 |
p. A2-
1 p.
|
artikel
|
| 24 |
CS3 THE EFFECT OF ORGAN THREATENING AND MENTAL HEALTH CO-MORBIDITIES ON MEDICAL COSTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
|
Zhang, L
|
|
2006
|
9 |
3 |
p. A3-
1 p.
|
artikel
|
| 25 |
CV2 IMPACT OF VENTRICULAR ARRHYTHMIA ON MORTALITY, HEALTH CARE UTILIZATION AND COST IN HOSPITALIZED ACUTE MYOCARDIAL INFARCTION PATIENTS
|
Wang, F
|
|
2006
|
9 |
3 |
p. A19-A20
nvt p.
|
artikel
|
| 26 |
CV1 INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION IN THE UNITED STATES
|
Balu, S
|
|
2006
|
9 |
3 |
p. A19-
1 p.
|
artikel
|
| 27 |
CV4 MANAGING CONGESTIVE HEART FAILURE: COHORT ANALYSIS OF USE AND COST OF HOSPITAL, EMERGENCY DEPARTMENT AND OBSERVATION UNIT CARE OVER TWELVE MONTHS
|
O'Brien, JA
|
|
2006
|
9 |
3 |
p. A20-
1 p.
|
artikel
|
| 28 |
CV3 SWITCHING, AUGMENTATION AND TITRATION OF LIPID LOWERING AGENTS OF MEDICARE/MEDICAID DUAL ELIGIBLE PATIENTS BY ETHNICITY
|
Mucha, L
|
|
2006
|
9 |
3 |
p. A20-
1 p.
|
artikel
|
| 29 |
DB3 QUALITY OF LIFE IN PEOPLE WITH AND AT RISK FOR TYPE 2 DIABETES: FINDINGS FROM THE STUDYTO HELP IMPROVE EARLY EVALUATION AND MANAGEMENT OF RISK FACTORS LEADING TO DIABETES (SHIELD)
|
Chapman, RH
|
|
2006
|
9 |
3 |
p. A9-
1 p.
|
artikel
|
| 30 |
DB2 SELF REPORTED PREDICTORS OF DEPRESSIVE SYMPTOMATOLOGY IN AN ELDERLY POPULATION WITH TYPE 2 DIABETES MELLITUS
|
Balkrishnan, R
|
|
2006
|
9 |
3 |
p. A9-
1 p.
|
artikel
|
| 31 |
DB4 STRESS AND COPING STRATEGIES ASSOCIATED WITH PHYSICAL AND MENTAL HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
Shah, BM
|
|
2006
|
9 |
3 |
p. A9-A10
nvt p.
|
artikel
|
| 32 |
Disclosure Information
|
|
|
2006
|
9 |
3 |
p. A174-A179
nvt p.
|
artikel
|
| 33 |
DISCLOSURE INFORMATION
|
|
|
2006
|
9 |
3 |
p. A174-A179
|
artikel
|
| 34 |
Economic Evaluation in Health Care: The Point of View of Informed Physicians
|
Fattore, Giovanni
|
|
2006
|
9 |
3 |
p. 157-167
11 p.
|
artikel
|
| 35 |
Economic Evaluation in Health Care: The Point of View of Informed Physicians
|
Fattore, Giovanni
|
|
2006
|
9 |
3 |
p. 157-167
|
artikel
|
| 36 |
FP3 AN AUDIT OF 106 ECONOMIC ANALYSES CONTAINED IN AMCP DOSSIER SUBMISSIONS 2002-2005
|
Colmenero, F
|
|
2006
|
9 |
3 |
p. A10-A11
nvt p.
|
artikel
|
| 37 |
FP2 COST-EFFECTIVENESS OF A GLAUCOMA-SCREENING PROGRAM: A MODEL EVALUATING THE RELATIVE CLINICAL AND ECONOMIC IMPACT IN COMMERCIAL VS. SENIOR MEMBER POPULATIONS
|
Goldberg, LD
|
|
2006
|
9 |
3 |
p. A10-
1 p.
|
artikel
|
| 38 |
FP4 NATIONAL ESTIMATES AND ASSOCIATED FACTORS OF ANTIPSYCHOTIC USE IN AMBULATORY CARE FROM 1996 TO 2003
|
Sankaranarayanan, J
|
|
2006
|
9 |
3 |
p. A11-
1 p.
|
artikel
|
| 39 |
FP1 USE OF MEDICATION COVERAGE METHODOLOGY IN MEASUREMENT OF PATIENT COMPLIANCE WITH PHARMACOTHERAPY
|
Stern, L
|
|
2006
|
9 |
3 |
p. A10-
1 p.
|
artikel
|
| 40 |
Health Resource Utilization and Medical Care Cost of Acute Care Elderly Unit Patients
|
Jayadevappa, Ravishankar
|
|
2006
|
9 |
3 |
p. 186-192
7 p.
|
artikel
|
| 41 |
Health Resource Utilization and Medical Care Cost of Acute Care Elderly Unit Patients
|
Jayadevappa, Ravishankar
|
|
2006
|
9 |
3 |
p. 186-192
|
artikel
|
| 42 |
HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES
|
Wang, J
|
|
2006
|
9 |
3 |
p. A13-
1 p.
|
artikel
|
| 43 |
HE1 ECONOMIC EVALUATION OF A 90-DAY RETAIL PRESCRIPTION DRUG PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING
|
Sun, SX
|
|
2006
|
9 |
3 |
p. A12-A13
nvt p.
|
artikel
|
| 44 |
HE2 ESTIMATING OUT-OF-POCKET PHARMACEUTICAL EXPENDITURES UNDERTHE NEW MEDICARE DRUG LAW FOR PATIENTS WITH MENTAL DISORDERS—AN ANALYSIS OF CLAIMS DATA FROM RETIREE MEDICAL PLANS
|
Gibson, TB
|
|
2006
|
9 |
3 |
p. A13-
1 p.
|
artikel
|
| 45 |
HE4 RACIAL/ETHNIC DISPARITIES IN LENGTH OF STAY AND COST OF INPATIENT CARE FOR INTRACEREBRAL HEMORRHAGE: EVIDENCE FROM THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE
|
Russell, MW
|
|
2006
|
9 |
3 |
p. A13-A14
nvt p.
|
artikel
|
| 46 |
HI1 ADULT ECONOMIC STATUS AND OBESITY IN THE UNITED STATES: 2000-2002
|
Wu, E
|
|
2006
|
9 |
3 |
p. A14-
1 p.
|
artikel
|
| 47 |
HI2 CLINICAL IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ≥65 YEARS WITH OVERACTIVE BLADDER
|
Joyce, AT
|
|
2006
|
9 |
3 |
p. A14-
1 p.
|
artikel
|
| 48 |
HI4 IMPACT OF PATIENT SELECTION CRITERIA AND MODEL SPECIFICATION ON COMPARISONS OF ALTERNATIVE THERAPIES:THE CASE OF ATYPICAL ANTIPSYCHOTICS
|
Marshall, TS
|
|
2006
|
9 |
3 |
p. A15-
1 p.
|
artikel
|
| 49 |
HI3 THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES
|
Gibson, TB
|
|
2006
|
9 |
3 |
p. A14-A15
nvt p.
|
artikel
|
| 50 |
HP3 DETERMINANTS OF GENERIC ENTRY IN LAST DECADE
|
Rhee, J
|
|
2006
|
9 |
3 |
p. A4-
1 p.
|
artikel
|
| 51 |
HP4 PRESCRIPTION DRUG INSURANCE AND ITS EFFECT ON UTILIZATION AND HEALTH OF THE ELDERLY
|
Khan, N
|
|
2006
|
9 |
3 |
p. A4-A5
nvt p.
|
artikel
|
| 52 |
HP1 RECENT POLICY INITIATIVES IN THE AUSTRALIAN NATIONAL REIMBURSEMENT SYSTEM THAT HAVE REDUCED COST DRAMATICALLY
|
Abela, M
|
|
2006
|
9 |
3 |
p. A3-A4
nvt p.
|
artikel
|
| 53 |
HP2 THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS IN AN EMPLOYED POPULATION
|
Crémieux, PY
|
|
2006
|
9 |
3 |
p. A4-
1 p.
|
artikel
|
| 54 |
ID4 COMPLIANCE WITH ANTIBIOTIC TREATMENT GUIDELINES IN MEDICARE MANAGED CARE PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN AMBULATORY SETTINGS
|
Wu, JH
|
|
2006
|
9 |
3 |
p. A21-A22
nvt p.
|
artikel
|
| 55 |
ID1 “GATEKEEPERS AND SENTINELS”: IMPLICATIONS FOR DRUG UTILIZATION POLICY IN THE COMMUNITY SETTING
|
Kahan, NR
|
|
2006
|
9 |
3 |
p. A20-A21
nvt p.
|
artikel
|
| 56 |
ID2 OUTCOMES ASSOCIATED WITH ANTIFUNGAL DRUG SWITCHING IN PATIENTS WITH SERIOUS CANDIDA INFECTIONS
|
He, J
|
|
2006
|
9 |
3 |
p. A21-
1 p.
|
artikel
|
| 57 |
ID3 TRENDS IN HIVTREATMENT EXPERIENCE AND OUTCOMES AS OBSERVED IN A SAMPLE OF PATIENTS FROM A US CLINICAL DATABASE
|
Martin, SC
|
|
2006
|
9 |
3 |
p. A21-
1 p.
|
artikel
|
| 58 |
Linguistic Validation of the US Spanish Work Productivity and Activity Impairment Questionnaire, General Health Version
|
Gawlicki, Mary C.
|
|
2006
|
9 |
3 |
p. 199-204
6 p.
|
artikel
|
| 59 |
Linguistic Validation of the US Spanish Work Productivity and Activity Impairment Questionnaire, General Health Version
|
Gawlicki, Mary C.
|
|
2006
|
9 |
3 |
p. 199-204
|
artikel
|
| 60 |
MH4 MEDICAL COSTS AND HOSPTALIZATION OF ADULTS DIAGNOSED WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER WHO RECEIVED ALTERNATIVE THERAPIES
|
Wu, E
|
|
2006
|
9 |
3 |
p. A16-
1 p.
|
artikel
|
| 61 |
MH1 NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDERAND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003
|
Toh, S
|
|
2006
|
9 |
3 |
p. A15-
1 p.
|
artikel
|
| 62 |
MH3 NICE'S COST-EFFECTIVENESS APPRAISAL OF CHOLINESTERASE INHIBITORS: ASKING THE RIGHT QUESTION
|
Getsios, D
|
|
2006
|
9 |
3 |
p. A16-
1 p.
|
artikel
|
| 63 |
MH2 USE PATTERNS AND OUTCOMES ASSOCIATED WITH TYPICAL DEPOT ANTIPSYCHOTIC AGENTS IN THE SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP)—AUSTRALIA
|
Christova, L
|
|
2006
|
9 |
3 |
p. A15-A16
nvt p.
|
artikel
|
| 64 |
ND3 A DESCRIPTION OF OFFICE VISIT RATESAND PRESCRIPTION USE FOR INSOMNIA AMONG RECIPIENTS OF A STATE MEDICAID PROGRAM
|
Roy, AN
|
|
2006
|
9 |
3 |
p. A22-
1 p.
|
artikel
|
| 65 |
ND2 EVALUATIONS OF THE PRESCRIBED DAILY DOSES OF TRANSDERMAL FENTANYL AND TRANSDERMAL BUPRENORPHINE IN CANCERAND NON-CANCER PATIENTS IN GERMANY: RESULTS FROM A RETROSPECTIVE DATABASE ANALYSIS
|
Haerdtl, G
|
|
2006
|
9 |
3 |
p. A22-
1 p.
|
artikel
|
| 66 |
ND4 IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON WORKPLACE PRODUCTIVITY: RESULTS FROM TWO U.S. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIALS
|
Gagne, JJ
|
|
2006
|
9 |
3 |
p. A23-
1 p.
|
artikel
|
| 67 |
ND1 THE INDIRECT COST BURDEN OF MIGRAINE AMONG SEVERAL LARGE U.S. EMPLOYERS
|
Hawkins, K
|
|
2006
|
9 |
3 |
p. A22-
1 p.
|
artikel
|
| 68 |
PAL1 DIAGNOSTIC TESTING FOR ALLERGIC RHINITIS: EVALUATING TEST DECISION AND TEST VALUE
|
Szeinbach, SL
|
|
2006
|
9 |
3 |
p. A99-
1 p.
|
artikel
|
| 69 |
PAR17 A COMPARISON OF HEALTH RELATED QUALITY OF LIFE (HRQOL) OF PERSONS WITH AND WITHOUT ARTHRITIS OR CHRONIC JOINT SYMPTOMS (CJS)
|
Tagliavia, NA
|
|
2006
|
9 |
3 |
p. A29-
1 p.
|
artikel
|
| 70 |
PAR12 A COST-EFFICACY ANALYSIS MODEL FOR ANTI-TNF AGENTS IN PSORIATIC ARTHRITIS
|
Arjunji, RV
|
|
2006
|
9 |
3 |
p. A27-A28
nvt p.
|
artikel
|
| 71 |
PAR2 ACTIVE SAFETY SURVEILLANCE FORTU-HUO-CHI-SHENG-TANG: A CHINESE HERBAL PRODUCT USED IN TREATIN OSTEOARTHRITIS OF KNEE
|
Hsieh, SC
|
|
2006
|
9 |
3 |
p. A24-
1 p.
|
artikel
|
| 72 |
PAR9 A PHARMACOECONOMIC EVALUATION FORTHE TREATMENT OF ARTICULAR PAIN IN PATIENTS WITH OSTEOARTHRITIS IN MEXICO
|
Contreras-Hernandez, I
|
|
2006
|
9 |
3 |
p. A26-A27
nvt p.
|
artikel
|
| 73 |
PAR13 A PROSPECTIVE STUDY COMPARING DRUG UTILIZATION PATTERNS AND COST OF TREATMENT OF PATIENTS FOR RHEUMATOID ARTHRITIS IN KERALA, INDIA
|
Meleth, TP
|
|
2006
|
9 |
3 |
p. A28-
1 p.
|
artikel
|
| 74 |
PAR20 BENEFIT-RISK-COST TRADE-OFF ANALYSES USING PATIENT PREFERENCES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
Arjunji, RV
|
|
2006
|
9 |
3 |
p. A30-
1 p.
|
artikel
|
| 75 |
PAR16 CAN OSTEOARTHRITIS PATIENTS EVALUATE TRADEOFFS BETWEEN NSAID RISKS AND BENEFITS?
|
Özdemir, S
|
|
2006
|
9 |
3 |
p. A29-
1 p.
|
artikel
|
| 76 |
PAR11 COST-EFFECTIVENESS ANALYSIS FOR TREATMENTS IN ANKYLOSING SPONDYLITIS
|
Vo, P
|
|
2006
|
9 |
3 |
p. A27-
1 p.
|
artikel
|
| 77 |
PAR4 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS IN THE UK
|
Porter, D
|
|
2006
|
9 |
3 |
p. A25-
1 p.
|
artikel
|
| 78 |
PAR5 COST-EFFECTIVENESS OF RITUXIMAB AS A NEW TREATMENT MODALITY FOR RHEUMATOID ARTHRITIS IN GERMANY
|
Rubbert, A
|
|
2006
|
9 |
3 |
p. A25-
1 p.
|
artikel
|
| 79 |
PAR10 COST-EFFECTIVENESS OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: A PAN-EUROPEAN ANALYSIS
|
Kielhorn, A
|
|
2006
|
9 |
3 |
p. A27-
1 p.
|
artikel
|
| 80 |
PAR18 HEALTH-RELATED QUALITY OF LIFE (HRQL) IN OSTEOARTHRITIS: A SYSTEMATIC REVIEW TO ASSESS THE MEASUREMENT PROPERTIES OFTHEWOMAC (WESTERN ONTARIO MCMASTER OSTEOARTHRITIS INDEX) FOR DISCRIMINATIVE AND EVALUATIVE RESEARCH
|
Suh, HS
|
|
2006
|
9 |
3 |
p. A29-A30
nvt p.
|
artikel
|
| 81 |
PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
|
Huels, J
|
|
2006
|
9 |
3 |
p. A25-A26
nvt p.
|
artikel
|
| 82 |
PAR7 MODELLING OF THE COST-EFFECTIVENESS OF RITUXIMAB FOR TREATMENT OF RHEUMATOID ARTHRITIS IN ITALY
|
De Vita, S
|
|
2006
|
9 |
3 |
p. A26-
1 p.
|
artikel
|
| 83 |
PAR15 PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS
|
Bellamy, N
|
|
2006
|
9 |
3 |
p. A28-A29
nvt p.
|
artikel
|
| 84 |
PAR1 PRESCRIPTION FOR LONGER LIFE: A DIAGNOSIS OF OSTEOARTHRITIS?
|
Lee, TA
|
|
2006
|
9 |
3 |
p. A24-
1 p.
|
artikel
|
| 85 |
PAR3 RETROSPECTIVE STUDY ON THE ADVERSE EVENTS OF ARTHRITIC PATIENTS TREATED WITH VIOXX AND OTHER ARTHRITIS PAINKILLERS
|
Griffin, B
|
|
2006
|
9 |
3 |
p. A24-A25
nvt p.
|
artikel
|
| 86 |
PAR8 USING MABTHERA IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN: RESULTS OF COST-EFFECTIVENESS DATA BASED ON MICRO-SIMULATION
|
Kielhorn, A
|
|
2006
|
9 |
3 |
p. A26-
1 p.
|
artikel
|
| 87 |
PAR11 WITHDRAWAL OF COX-2 INHIBITOR ROFECOXIBAND VALDECOXIB: IMPACT ON NSAIDAND PPI PRESCRIPTIONS AND EXPENDITURES
|
Sun, SX
|
|
2006
|
9 |
3 |
p. A28-
1 p.
|
artikel
|
| 88 |
PAS13 ASSOCIATION OF MEDICATION ADHERENCE WITH WORKPLACE PRODUCTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ASTHMA
|
Joshi, AV
|
|
2006
|
9 |
3 |
p. A103-A104
nvt p.
|
artikel
|
| 89 |
PAS10 A SYSTEMATIC OVERVIEW OF THE MEASUREMENT PROPERTIES OF THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN ASTHMA
|
Wang, SM
|
|
2006
|
9 |
3 |
p. A102-A103
nvt p.
|
artikel
|
| 90 |
PAS7 COMPUTERIZED DECISION SUPPORT FOR ASTHMA MANAGEMENT
|
Duwuri, VRSK
|
|
2006
|
9 |
3 |
p. A101-A102
nvt p.
|
artikel
|
| 91 |
PAS2 DRUG ADVERSE EVENTS MODIFYTHE TREATMENT AND COMPLIANCE OF ASTHMA PATIENTS
|
Laitinen, T
|
|
2006
|
9 |
3 |
p. A100-
1 p.
|
artikel
|
| 92 |
PAS4 ECONOMETRIC MODELING IN CHRONIC ASTHMA ALLOWS COMPARISONS BETWEEN DIFFERENT THERAPY GROUPS
|
Palmu, PJ
|
|
2006
|
9 |
3 |
p. A100-A101
nvt p.
|
artikel
|
| 93 |
PAS3 ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA
|
Miller, B
|
|
2006
|
9 |
3 |
p. A100-
1 p.
|
artikel
|
| 94 |
PAS8 IMPROVING ASTHMA SELF-MANAGEMENT AND PATIENT OUTCOMES USING AN AUTOMATED PROGRAM
|
Arnold, RJG
|
|
2006
|
9 |
3 |
p. A102-
1 p.
|
artikel
|
| 95 |
PAS1 LEAVING AGAINST MEDICAL ADVICE (LAMA) IN ASTHMA EXACERBATION: CHARACTERISTICS AND DETERMINANTS OF LEAVERS
|
Tano, BD
|
|
2006
|
9 |
3 |
p. A100-
1 p.
|
artikel
|
| 96 |
PAS11 PROPENSITY SCORE MATCHING WITH MORE THAN TWO CATEGORIES
|
Baser, O
|
|
2006
|
9 |
3 |
p. A103-
1 p.
|
artikel
|
| 97 |
PAS5 RELATIONSHIP OF PATIENT CHARACTERISTICS AND RESOURCE USE IN SEVERE ASTHMA
|
White, AF
|
|
2006
|
9 |
3 |
p. A101-
1 p.
|
artikel
|
| 98 |
PAS9 THE PERFORMANCE OF BOOTSTRAPPING IN DISCRETE CHOICE MODELS
|
Baser, O
|
|
2006
|
9 |
3 |
p. A102-
1 p.
|
artikel
|
| 99 |
PAS12 TREATMENT PERSISTENCE AND COMPLIANCE WITH MEDICATIONS FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Cramer, JA
|
|
2006
|
9 |
3 |
p. A103-
1 p.
|
artikel
|
| 100 |
PCN31 A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES
|
Baser, O
|
|
2006
|
9 |
3 |
p. A113-
1 p.
|
artikel
|
| 101 |
PCN3 AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR DELAYED NAUSEA AND VOMITING USING ELECTRONIC MEDICAL RECORDS
|
Forsyth, M
|
|
2006
|
9 |
3 |
p. A104-
1 p.
|
artikel
|
| 102 |
PCN43 A SYSTEMATIC REVIEW OF THE EORTC QLQ-BR23: DESCRIPTIVE HEALTH RELATED QUALITY OF LIFE INSTRUMENT USED IN BREAST CANCER
|
Kawatkar, AA
|
|
2006
|
9 |
3 |
p. A117-
1 p.
|
artikel
|
| 103 |
PCN39 A SYSTEMATIC REVIEW OF THE UCLA PROSTATE CANCER INDEX'S MEASUREMENT PROPERTIES
|
Epstein, JD
|
|
2006
|
9 |
3 |
p. A116-
1 p.
|
artikel
|
| 104 |
PCN18 CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY
|
Nuyts, G
|
|
2006
|
9 |
3 |
p. A109-
1 p.
|
artikel
|
| 105 |
PCN19 COLONOSCOPYAND FLEXIBLE SIGMOIDOSCOPY: A MICROCOSTING STUDY EVALUATING DIAGNOSTIC PROCEDURAL COSTS IN AN OUTPATIENT ENDOSCOPY CLINIC
|
Sambrook, JC
|
|
2006
|
9 |
3 |
p. A109-A110
nvt p.
|
artikel
|
| 106 |
PCN13 COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY
|
Annemans, L
|
|
2006
|
9 |
3 |
p. A107-A108
nvt p.
|
artikel
|
| 107 |
PCN12 COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL) RECEIVING CHOP
|
Lyman, GH
|
|
2006
|
9 |
3 |
p. A107-
1 p.
|
artikel
|
| 108 |
PCN8 COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN
|
Ikeda, S
|
|
2006
|
9 |
3 |
p. A106-
1 p.
|
artikel
|
| 109 |
PCN11 COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER
|
Kerrigan, M
|
|
2006
|
9 |
3 |
p. A107-
1 p.
|
artikel
|
| 110 |
PCN10 COST-EFFECTIVENESS OF GEMCITABINE-PACLITAXEL COMBINATION IN THE TREATMENT OF ADVANCED BREAST CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY
|
Davey, P
|
|
2006
|
9 |
3 |
p. A106-A107
nvt p.
|
artikel
|
| 111 |
PCN14 COST-EFFECTIVENESS OFTAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER
|
Kawatkar, AA
|
|
2006
|
9 |
3 |
p. A108-
1 p.
|
artikel
|
| 112 |
PCN20 COSTS OF THE DIFFERENT TREATMENTS FOR PATIENTS WITH BREAST CANCER IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
|
Salinas-Escudero, G
|
|
2006
|
9 |
3 |
p. A110-
1 p.
|
artikel
|
| 113 |
PCN24 DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT—AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL
|
Brentani, A
|
|
2006
|
9 |
3 |
p. A111-
1 p.
|
artikel
|
| 114 |
PCN36 DEVELOPING HEALTH STATE DESCRIPTIONS FOR METASTATIC COLORECTAL CANCER: QUALITATIVE STUDY
|
Lloyd, A
|
|
2006
|
9 |
3 |
p. A115-
1 p.
|
artikel
|
| 115 |
PCN35 DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC, NEUROENDOCRINE TUMOR QUESTIONNAIRE (QOL-NET). TO MEASURE PATIENTS' PERCEPTION OF THE EFFECTS OF DISEASE ON THEIR QUALITY OF LIFE (QOL)
|
Vinik, EJ
|
|
2006
|
9 |
3 |
p. A114-A115
nvt p.
|
artikel
|
| 116 |
PCN21 4D LOCALIZATION SYSTEM WITH TRANSPONDERS FOR CONTINUOUS TARGET LOCALIZATION FOR SET-UP AND TRACKING DURING RADIATION THERAPY: EARLY HEALTH TECHNOLOGY ASSESSMENT
|
Williams, E
|
|
2006
|
9 |
3 |
p. A110-
1 p.
|
artikel
|
| 117 |
PCN9 ECONOMIC EVALUATION OFANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
|
Mody, RR
|
|
2006
|
9 |
3 |
p. A106-
1 p.
|
artikel
|
| 118 |
PCN16 ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS: A MEDICARE PERSPECTIVE
|
Pelletier, EM
|
|
2006
|
9 |
3 |
p. A108-A109
nvt p.
|
artikel
|
| 119 |
PCN2 EFFECTIVENESS OF A COMMUNITY—BASED PROSTATE CANCER EDUCATION KIOSK FOR AFRICAN AMERICAN MEN: ANALYSES OF COST, SATISFACTION, QUALITY, KNOWLEDGE, AND INTENTION VARIABLES
|
Young, S
|
|
2006
|
9 |
3 |
p. A104-
1 p.
|
artikel
|
| 120 |
PCN45 EFFECT OF AGE ON PREFERENCES FOR HEALTH OUTCOMES IN PROSTATE CANCER
|
Krahn, MD
|
|
2006
|
9 |
3 |
p. A118-
1 p.
|
artikel
|
| 121 |
PCN41 EQ-5D IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ASSESSMENT OF VALIDITY AND RESPONSIVENESS
|
Sundaram, M
|
|
2006
|
9 |
3 |
p. A116-
1 p.
|
artikel
|
| 122 |
PCN1 ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG CANCER ADJUVANT TREATMENTS IN PRACTICE USING INSTRUMENTAL VARIABLE METHODS
|
Brooks, JM
|
|
2006
|
9 |
3 |
p. A104-
1 p.
|
artikel
|
| 123 |
PCN37 ESTIMATION OF A SET OF PATIENT-BASED UTILITY WEIGHTS FOR THE FACT-G
|
Dobrez, D
|
|
2006
|
9 |
3 |
p. A115-
1 p.
|
artikel
|
| 124 |
PCN17 EVALUATING THE COST OF CARE FOR EARLY AND LATE STAGE OROPHARYNGEAL CANCER IN THE CALIFORNIA MEDICAID POPULATION
|
Epstein, JD
|
|
2006
|
9 |
3 |
p. A109-
1 p.
|
artikel
|
| 125 |
PCN29 GAPS IN THE ECONOMIC EVALUATION OF PROSTATE CANCER
|
Komatsuzaki, Y
|
|
2006
|
9 |
3 |
p. A112-A113
nvt p.
|
artikel
|
| 126 |
PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS
|
Furlong, W
|
|
2006
|
9 |
3 |
p. A112-
1 p.
|
artikel
|
| 127 |
PCN6 HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH CANCERAND PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD)
|
Smith, J
|
|
2006
|
9 |
3 |
p. A105-
1 p.
|
artikel
|
| 128 |
PCN44 IMPROVEMENT IN SENSORY PAIN RATING AFTER PALLIATIVE RADIONUCLIDE THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER
|
Papatheofanis, FJ
|
|
2006
|
9 |
3 |
p. A117-
1 p.
|
artikel
|
| 129 |
PCN26 INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT VERSUS CLINICIAN ASSESSMENT
|
Rae, CS
|
|
2006
|
9 |
3 |
p. A111-A112
nvt p.
|
artikel
|
| 130 |
PCNI5 THE ANNUAL HEALTH INSURANCE COST OF COLORECTAL CANCER TREATMENT IN HUNGARY:A COST OF ILLNESS STUDY
|
Boncz, I
|
|
2006
|
9 |
3 |
p. A108-
1 p.
|
artikel
|
| 131 |
PCN33 MAPPING FACT-PAND EORTC QLQ-C30TOTHE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS
|
Wu, E
|
|
2006
|
9 |
3 |
p. A114-
1 p.
|
artikel
|
| 132 |
PCN32 MODELING AND ESTIMATING PREFERENCES OVER TREATMENTS FOR BREAST CANCER: APPLIED CONJOINT ANALYSIS WITH PHYSICIANS IN EUROPE AND UNITED STATES
|
Walzer, S
|
|
2006
|
9 |
3 |
p. A113-A114
nvt p.
|
artikel
|
| 133 |
PCN46 ONLINE REPORTING OFTOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY
|
Basch, E
|
|
2006
|
9 |
3 |
p. A118-
1 p.
|
artikel
|
| 134 |
PCN42 PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS: DATA FROM CAPSURE™
|
Sadetsky, N
|
|
2006
|
9 |
3 |
p. A117-
1 p.
|
artikel
|
| 135 |
PCN38 PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP
|
Baser, O
|
|
2006
|
9 |
3 |
p. A115-
1 p.
|
artikel
|
| 136 |
PCN5 QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH BREAST CANCERAND ITS ECONOMIC CONSEQUENCES IN MEXICO
|
Contreras-Hernandez, I
|
|
2006
|
9 |
3 |
p. A105-
1 p.
|
artikel
|
| 137 |
PCN25 REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A NATIONWIDE SAMPLE OF PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY: RESULTS FROM A LARGE RETROSPECTIVE OBSERVATIONAL STUDY
|
McLaughlin, T
|
|
2006
|
9 |
3 |
p. A111-
1 p.
|
artikel
|
| 138 |
PCN4 RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF ENDOMETRIAL CANCER
|
Wang, C
|
|
2006
|
9 |
3 |
p. A105-
1 p.
|
artikel
|
| 139 |
PCN28 REVIEW OF ECONOMIC APPRAISALS OF CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER
|
Hornberger, J
|
|
2006
|
9 |
3 |
p. A112-
1 p.
|
artikel
|
| 140 |
PCN22 THE EFFECT OF EFFICIENCY OF ACCESS TO CARE
|
Younis, M
|
|
2006
|
9 |
3 |
p. A110-
1 p.
|
artikel
|
| 141 |
PCN23 THE EFFECT OF ORGANIZED MAMMOGRAPHY SCREENING ON THE NUMBER OF BREAST SURGERIES
|
Boncz, L
|
|
2006
|
9 |
3 |
p. A111-
1 p.
|
artikel
|
| 142 |
PCN40 THE IMPACT OF HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER ON HEALTH-RELATED QUALITY OF LIFE: A REVIEW OF VALIDATED INSTRUMENTS CURRENTLY AVAILABLE
|
Rofail, D
|
|
2006
|
9 |
3 |
p. A116-
1 p.
|
artikel
|
| 143 |
PCN34 VALIDATION OF AN INTERNET-BASED PATIENT HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE: DATA FROM CAPSURE
|
Broering, JM
|
|
2006
|
9 |
3 |
p. A114-
1 p.
|
artikel
|
| 144 |
PCV55 ADHERENCE MEASURES: SO MANYTO CHOOSE FROM, WHAT IS THE DIFFERENCE?
|
Hutchins, PS
|
|
2006
|
9 |
3 |
p. A135-
1 p.
|
artikel
|
| 145 |
PCV58 ADHERENCE TO EVIDENCE-BASED STATIN GUIDELINES REDUCES RISK FORACUTE MYOCARDIAL INFARCTION WITH AT LEAST 50%.
|
Penning-van Beest, FJ
|
|
2006
|
9 |
3 |
p. A136-
1 p.
|
artikel
|
| 146 |
PCV24 AFRICAN AMERICANS' RESPONSES TO DIRECT-TO-CONSUMER ADVERTISING (DTCA) OF LIPITOR®
|
Yang, Y
|
|
2006
|
9 |
3 |
p. A125-A126
nvt p.
|
artikel
|
| 147 |
PCV29 ANALYSES FOR PRICE AND UTILIZATION OF CALCIUM CHANNEL BLOCKERS IN US MEDICAID PROGRAMS
|
Chen, Y
|
|
2006
|
9 |
3 |
p. A127-
1 p.
|
artikel
|
| 148 |
PCV23 AN ANALYSIS OF RESOURCE USE IN THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT) IN BRAZIL
|
Fonseca, M
|
|
2006
|
9 |
3 |
p. A125-
1 p.
|
artikel
|
| 149 |
PCV47 AN APPROACH TO GENERALIZE CLINICAL TRIAL RESULTS TO NON-STUDY POPULATIONS FOR COST-EFFECTIVENESS EVALUATIONS—THE CASE OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS)
|
Johnson, SJ
|
|
2006
|
9 |
3 |
p. A133-
1 p.
|
artikel
|
| 150 |
PCV4 A NATIONAL STUDY PREDICTING THE INFLUENCE OF PAYMENT SOURCES ON THE THIAZIDE DIURETICS UTILIZATION FOR HYPERTENSION
|
Rahman, A
|
|
2006
|
9 |
3 |
p. A119-
1 p.
|
artikel
|
| 151 |
PCV43 AN EMPIRICAL EVALUATION OF THE EXPECTED VALUE OF PERFECT INFORMATION
|
Lundy, J
|
|
2006
|
9 |
3 |
p. A131-A132
nvt p.
|
artikel
|
| 152 |
PCV7 A PROSPECTIVE STUDY EVALUATING STREPTOKINASE THERAPY ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH MYOCARDIAL INFARCTION AT A TERTIARY CARE REFERRAL HOSPITAL IN KERALA, INDIA
|
Chandrasekhar, R
|
|
2006
|
9 |
3 |
p. A120-
1 p.
|
artikel
|
| 153 |
PCV12 ASSESSMENT OF THE EFFECTS OF ROFECOXIB, CELECOXIB AND NAPROXEN ON BLOOD PRESSURE AND CARDIOVASCULAR RISK: A RETROSPECTIVE CHART REVIEW STUDY
|
Brown, RR
|
|
2006
|
9 |
3 |
p. A122-
1 p.
|
artikel
|
| 154 |
PCV63 ASSOCIATION OFANTIHYPERTENSIVE MEDICATION CLASS WITH BLOOD PRESSURE CONTROL AND PERSISTENCE ON MONOTHERAPY
|
Smith, KL
|
|
2006
|
9 |
3 |
p. A138-
1 p.
|
artikel
|
| 155 |
PCV66 A SYSTEMATIC REVIEW OF THE DISEASE-SPECIFIC AND THE GENERIC QUALITY-OF-LIFE INSTRUMENTS IN CONGESTIVE HEART FAILURE
|
Gu, NY
|
|
2006
|
9 |
3 |
p. A139-
1 p.
|
artikel
|
| 156 |
PCV15 ATRIAL VERSUS DUAL CHAMBER PACING IN SINUS NODE DISEASE
|
Rucinski, P
|
|
2006
|
9 |
3 |
p. A123-
1 p.
|
artikel
|
| 157 |
PCV68 BENEFICIAL IMPACT ON BLOOD PRESSURE CONTROL AMONG MEN PRESCRIBED SILDENAFIL CITRATE
|
Scranton, R
|
|
2006
|
9 |
3 |
p. A139-
1 p.
|
artikel
|
| 158 |
PCV9 CARDIOVASCULAR RISK PREDICTED BY ADHERENCE TO STATINS IN A MEDICAID POPULATION
|
Shaya, FT
|
|
2006
|
9 |
3 |
p. A121-
1 p.
|
artikel
|
| 159 |
PCV13 CLOPIDOGREL THERAPY AND HEALTH CARE COSTS FOLLOWING AN ACUTE CORONARY SYNDROME EVENT
|
Shetty, SS
|
|
2006
|
9 |
3 |
p. A122-
1 p.
|
artikel
|
| 160 |
PCV21 COSTS OF DIAGNOSTIC PROCEDURES OF INTERVENTIONIST CARDIOLOGY IN THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
|
Mould, J
|
|
2006
|
9 |
3 |
p. A124-A125
nvt p.
|
artikel
|
| 161 |
PCV17 DECISION ANALYSIS TO COMPARE THE COST-EFFECTIVENESS OF THE STATINS AVAILABLE BY PRESCRIPTION VERSUS OVER THE COUNTER BASED FROM A SOCIETAL PERSPECTIVE
|
Gandhi, P
|
|
2006
|
9 |
3 |
p. A123-
1 p.
|
artikel
|
| 162 |
PCV61 DETERMINANTS OF ADHERENCE TO STATINS INA MEDICAID MANAGED CARE POPULATION
|
Samant, ND
|
|
2006
|
9 |
3 |
p. A137-
1 p.
|
artikel
|
| 163 |
PCV54 DETERMINANTS OF TREATMENT PERSISTENCE INA GERMAN HYPERTENSIVE POPULATION
|
Annemans, L
|
|
2006
|
9 |
3 |
p. A135-
1 p.
|
artikel
|
| 164 |
PCV34 DEVELOPING HOSPICE DRUG FORMULARY USING MULTI-ATTRIBUTE UTILITYTHEORY (MAUT) METHODOLOGY
|
Khandelwal, NG
|
|
2006
|
9 |
3 |
p. A129-
1 p.
|
artikel
|
| 165 |
PCV57 DOES 90-DAY PRESCRIPTION SUPPLY AT RETAIL IMPROVE COMPLIANCE IN A MANAGED CARE SETTING]
|
Thiebaud, P
|
|
2006
|
9 |
3 |
p. A136-
1 p.
|
artikel
|
| 166 |
PCV32 DRUG PRICE AND UTILIZATION OF ACE INHIBITORS IN US MEDICAID POPULATION
|
Li, X
|
|
2006
|
9 |
3 |
p. A128-
1 p.
|
artikel
|
| 167 |
PCV31 DRUG PRICE AND UTILIZATION OF BETA BLOCKERS IN US MEDICAID PROGRAMS
|
Jing, Y
|
|
2006
|
9 |
3 |
p. A128-
1 p.
|
artikel
|
| 168 |
PCV28 ECONOMIC EVALUATION OF AN INTERDISCIPLINARY APPROACH TO HEART FAILURE MANAGEMENT
|
Sutton, SS
|
|
2006
|
9 |
3 |
p. A127-
1 p.
|
artikel
|
| 169 |
PCV18 ECONOMIC EVALUATION OF ORAL THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION
|
Harriett, J
|
|
2006
|
9 |
3 |
p. A124-
1 p.
|
artikel
|
| 170 |
PCV11 EVALUATION OF A MAIL-BASED WARFARIN (COUMADIN®) PATIENT EDUCATION INITIATIVE IN A MANAGED CARE SETTING
|
Hoffman, L
|
|
2006
|
9 |
3 |
p. A121-A122
nvt p.
|
artikel
|
| 171 |
PCV60 IMPACT OF ADHERENCE TO ANTIHYPERLIPIDEMIC DRUGS ON TOTAL PHARMACY AND MEDICAL COSTS
|
El Khoury, AC
|
|
2006
|
9 |
3 |
p. A137-
1 p.
|
artikel
|
| 172 |
PCV38 INITIAL PHARMACEUTICAL TREATMENT OF SIMPLE HYPERTENSION
|
Zhang, K
|
|
2006
|
9 |
3 |
p. A130-
1 p.
|
artikel
|
| 173 |
PCV22 INPATIENT MANAGEMENT OF TRANSMURAL AND SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION (AMI): DIFFERENCES IN RESOURCE USE AND COST
|
O'Brien, JA
|
|
2006
|
9 |
3 |
p. A125-
1 p.
|
artikel
|
| 174 |
PCV59 LONG-TERM CARDIOVASCULAR OUTCOMES OF COMPLIANCE AND PERSISTENCE WITH HYPERTENSION THERAPY
|
Halpern, MT
|
|
2006
|
9 |
3 |
p. A136-A137
nvt p.
|
artikel
|
| 175 |
PCV10 LOSS OF COMBINED OPTIMAL LIPID VALUE ACHIEVEMENT AND THE RISK OF CARDIOVASCULAR EVENTS
|
Charland, SL
|
|
2006
|
9 |
3 |
p. A121-
1 p.
|
artikel
|
| 176 |
PCV20 MARKOV-BASED ECONOMIC ANALYSIS OF NESIRITIDE IN ACUTE DECOMPENSATED HEART FAILURE
|
Blackburn, JC
|
|
2006
|
9 |
3 |
p. A124-
1 p.
|
artikel
|
| 177 |
PCV52 MEDICATION ADHERENCE: PREDICTORS AND IMPACT ON HOSPITALIZATION RISK
|
Agarwal, S
|
|
2006
|
9 |
3 |
p. A134-
1 p.
|
artikel
|
| 178 |
PCV6 MODELED ACHIEVEMENT OF OPTIMAL LIPID VALUES WITH EXTENDED-RELEASE NIACIN/LOVASTATIN VERSUS SIMVASTATIN/EZETIMIBE COMBINATION THERAPY IN AT-RISK PATIENTS
|
Stanek, EJ
|
|
2006
|
9 |
3 |
p. A120-
1 p.
|
artikel
|
| 179 |
PCV19 ONE-YEAR COSTS FORACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT REVASCULARIZATION DURING THE INITIAL HOSPITALIZATION
|
Sidney, S
|
|
2006
|
9 |
3 |
p. A124-
1 p.
|
artikel
|
| 180 |
PCV8 OUTCOMES OF CONGESTIVE HEART FAILURE INPATIENTS TREATED WITH NESIRITIDE
|
Mahoney, A
|
|
2006
|
9 |
3 |
p. A120-A121
nvt p.
|
artikel
|
| 181 |
PCV51 OUTPATIENT DISCONTINUATION AND RESTARTING OF POST-MYOCARDIAL INFARCTION BETA-BLOCKERTHERAPY
|
Do, TP
|
|
2006
|
9 |
3 |
p. A134-
1 p.
|
artikel
|
| 182 |
PCV49 PATIENT ADHERENCE TO AHA GUIDELINES PRE-AND POST AMI
|
Kuznik, A
|
|
2006
|
9 |
3 |
p. A133-
1 p.
|
artikel
|
| 183 |
PCV65 PATIENT ADHERENCE WITH ANTIDIABETIC, ANTIHYPERTENSIVE, AND LIPID-LOWERING MEDICATIONS: EVALUATION OF VETERANS WITH TYPE 2 DIABETES
|
Wang, Z
|
|
2006
|
9 |
3 |
p. A138-
1 p.
|
artikel
|
| 184 |
PCV5 PATIENT RISK ASSESSMENT AND ENGAGEMENT IN PRIMARY CARE MANAGEMENT OF CARDIOVASCULAR RISK
|
Stewart, WF
|
|
2006
|
9 |
3 |
p. A119-A120
nvt p.
|
artikel
|
| 185 |
PCV56 PERSISTENCE WITH NEWLY-INITIATED EXTENDED-RELEASE NIACIN VERSUS OTHER LIPID MODIFYING DRUG CLASSES IN CLINICAL PRACTICE
|
Kamal-Bahl, S
|
|
2006
|
9 |
3 |
p. A135-A136
nvt p.
|
artikel
|
| 186 |
PCV39 PREDICTING ANTIHYPERTENSIVE DRUG UTILIZATION: AN APPLICATION OF LATENT CLASS MODELS
|
Thiebaud, P
|
|
2006
|
9 |
3 |
p. A130-
1 p.
|
artikel
|
| 187 |
PCV42 PREDICTING HIGH COSTS IN CALIFORNIA MEDICAID PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)
|
Nichol, MB
|
|
2006
|
9 |
3 |
p. A131-
1 p.
|
artikel
|
| 188 |
PCV67 PREDICTORS OF HIGH BLOOD PRESSURE KNOWLEDGE IN HYPERTENSIVE PATIENTS
|
Gu, A
|
|
2006
|
9 |
3 |
p. A139-
1 p.
|
artikel
|
| 189 |
PCV26 PRESCRIBING PATTERNS FOR ANTIHYPERTENSIVE DRUGS AFTERTHE PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) IN REGION EMILIA ROMAGNA (RER), ITALY
|
Maio, V
|
|
2006
|
9 |
3 |
p. A126-
1 p.
|
artikel
|
| 190 |
PCV33 PRESCRIPTION DRUG INSURANCE STATUS AND UTILIZATION OF ANTI-HYPERLIPIDEMICS: RESULTS FROM THE 2000 MEDICAL EXPENDITURE PANEL SURVEY
|
Gupta, K
|
|
2006
|
9 |
3 |
p. A128-
1 p.
|
artikel
|
| 191 |
PCV41 PROVISION OF DIET/NUTRITION AND EXERCISE COUNSELING FOR PATIENTS WITH DYSLIPIDEMIA BY AMBULATORY CARE PHYSICIANS IN THE UNITED STATES
|
Lee, LJ
|
|
2006
|
9 |
3 |
p. A131-
1 p.
|
artikel
|
| 192 |
PCV36 RATE OF LOW-DENSITY LIPOPROTEIN (LDL) GOAL ATTAINMENT WITH LIPID LOWERING THERAPIES AT A LI PID CLINIC IN A PUBLIC HOSPITAL OF HONG KONG—POSSIBLE ROLE OF A CLINICAL PHARMACY SERVICE
|
Lee, VWY
|
|
2006
|
9 |
3 |
p. A129-
1 p.
|
artikel
|
| 193 |
PCV45 RELIABILITY AND VALIDITY OF TAIWAN VERSION OF TREATMENT-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR PATIENTS RECEIVING ORAL ANTICOAGULATION
|
Chu, YW
|
|
2006
|
9 |
3 |
p. A132-
1 p.
|
artikel
|
| 194 |
PCV2 RETROSPECTIVE STUDY OF PATIENTS WITH CABG REOPERATION AND OUTCOMES
|
He, J
|
|
2006
|
9 |
3 |
p. A118-A119
nvt p.
|
artikel
|
| 195 |
PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE
|
Ohsfeldt, RL
|
|
2006
|
9 |
3 |
p. A123-
1 p.
|
artikel
|
| 196 |
PCV35 SINGLE SOURCE COST ESTIMATES FOR EVENTS ACROSS VARIOUS CONDITIONS REQUIRING THROMBOEMBOLIC PROPHYLAXIS AND TREATMENT
|
Patel, NM
|
|
2006
|
9 |
3 |
p. A129-
1 p.
|
artikel
|
| 197 |
PCV53 STATIN NONCOMPLIANCE AFTER CHD HOSPITALIZATION AND SUBSEQUENT HOSPITALIZATION AMONG NEW STATIN USERS
|
Ye, X
|
|
2006
|
9 |
3 |
p. A134-A135
nvt p.
|
artikel
|
| 198 |
PCV50 STATIN THERAPY PERSISTENCE IN A MANAGED CARE POPULATION
|
Wang, SM
|
|
2006
|
9 |
3 |
p. A133-A134
nvt p.
|
artikel
|
| 199 |
PCV37 SURVEY OF PHYSICIAN ATTITUDES AND PRACTICES IN LIPID LOWERING MANAGEMENT
|
Lewis, BE
|
|
2006
|
9 |
3 |
p. A130-
1 p.
|
artikel
|
| 200 |
PCV46 THE ALABAMA COLLABORATION FOR CARDIOVASCULAR EQUALITY PROJECT: ADAPTING AN ELECTRONIC MEDICAL RECORD ABSTRACTION TOOL FOR USE IN AN URBAN COMMUNITY HOSPITAL SETTING
|
Hullett, S
|
|
2006
|
9 |
3 |
p. A132-
1 p.
|
artikel
|
| 201 |
PCV44 THE CASE OF LI PI D-LOWERING THERAPY: A COMPARISON OF ADHERENCE MEASUREMENT METHODOLOGIES USING ADMINISTRATIVE CLAIMS DATA
|
LaFleur, J
|
|
2006
|
9 |
3 |
p. A132-
1 p.
|
artikel
|
| 202 |
PCV27 THE IMPACT OF DOSE INCREASE ON THE COST-EFFECTIVENESS OF STATINS
|
Lamotte, M
|
|
2006
|
9 |
3 |
p. A126-A127
nvt p.
|
artikel
|
| 203 |
PCV3 THE IMPACT OF MYOCARDIAL PERFUSION IMAGING FOR DETECTION OF CORONARY ARTERY DISEASE ON THE HEALTH OUTCOMES OF ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES
|
Marangos, PJ
|
|
2006
|
9 |
3 |
p. A119-
1 p.
|
artikel
|
| 204 |
PCV64 THE LEVEL AND LONG-TERM DYNAMICS OF THE QUALITY OF LIFE AS PREDICTORS OF ADHERENCE TO ROUTINE HYPERTENSION MANAGEMENT
|
Golubev, SA
|
|
2006
|
9 |
3 |
p. A138-
1 p.
|
artikel
|
| 205 |
PCV30 TREND ANALYSIS OF PRICE AND UTILIZATION OF STATIN DRUGS IN U.S. MEDICAID PROGRAMS
|
Jing, Y
|
|
2006
|
9 |
3 |
p. A127-
1 p.
|
artikel
|
| 206 |
PCV62 UNDERSTANDING PATIENT BELIEFS TO DESIGN MEDICATION ADHERENCE MESSAGING
|
Foley, K
|
|
2006
|
9 |
3 |
p. A137-A138
nvt p.
|
artikel
|
| 207 |
PCV25 USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY HYPERTENSIVE PATIENTS IN THE UNITED STATES
|
Iyer, RG
|
|
2006
|
9 |
3 |
p. A126-
1 p.
|
artikel
|
| 208 |
PCV1 USING ANTI-COAGULANTS AS PROPHYLAXIS FOR DVT/PE
|
Burleigh, E
|
|
2006
|
9 |
3 |
p. A118-
1 p.
|
artikel
|
| 209 |
PCV40 VARIATION OF COST-TO-CHARGE RATIO FOR CABG PATIENT BY HOSPITAL TYPE OVERTIME
|
Huang, X
|
|
2006
|
9 |
3 |
p. A130-A131
nvt p.
|
artikel
|
| 210 |
PDB38 A LITERATURE REVIEW OF TREATMENT SATISFACTION, ADHERENCE AND QOL INSTRUMENTS USED IN TYPE I AND 2 DIABETES
|
Staniek, V
|
|
2006
|
9 |
3 |
p. A42-A43
nvt p.
|
artikel
|
| 211 |
PDB12 A MARKOV MODEL TO ASSESS THE COST-EFFECTIVENESS OF A CONTINUOUS GLUCOSE MONITORING SYSTEM WITH TRENDING AND RATE INFORMATION WHEN USED TO PREDICT AND PREVENT HYPO-AND HYPERGLYCEMIA IN PATIENTS WITH TYPE I DIABETES
|
Marangos, PJ
|
|
2006
|
9 |
3 |
p. A34-
1 p.
|
artikel
|
| 212 |
PDB21 ANTIDIABETIC MEDI CATION PRESCRIBING TRENDS IN FRANCE: EVIDENCE FROM PRIMARY CARE PHYSICIANS
|
Secnik, K
|
|
2006
|
9 |
3 |
p. A37-
1 p.
|
artikel
|
| 213 |
PDB26 ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—A METHODOLOGICAL COMPARISON USING A CLAIMS DATABASE
|
Yang, M
|
|
2006
|
9 |
3 |
p. A38-A39
nvt p.
|
artikel
|
| 214 |
PDB27 ANTIPSYCHOTIC UTILIZATION AND TREATMENT-EMERGENT DIABETES—COMPARISON OF RESULTS WITH AND WITHOUT PROPENSITY SCORING
|
Yang, M
|
|
2006
|
9 |
3 |
p. A39-
1 p.
|
artikel
|
| 215 |
PDB31 ASSOCIATION BETWEEN RACE AND MEDICATION ADHERENCE IN TYPE 2 DIABETES MEDICAID ENROLLEES
|
Shenolikar, R
|
|
2006
|
9 |
3 |
p. A40-
1 p.
|
artikel
|
| 216 |
PDB32 A SYSTEMATIC REVIEW OF ADHERENCE WITH DIABETES TREATMENT AND THE IMPACT OF NON-ADHERENCE ON HEALTH CARE COSTS
|
Lee, WC
|
|
2006
|
9 |
3 |
p. A40-A41
nvt p.
|
artikel
|
| 217 |
PDB16 BASAL BOLUS THERAPY AMONG TYPE I DIABETES PATIENTS: A COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF ANALOG-AND HUMAN-BASED INSULIN REGIMENS
|
Valentine, W
|
|
2006
|
9 |
3 |
p. A35-
1 p.
|
artikel
|
| 218 |
PDB20 BLOOD GLUCOSE MONITORING RECOMMENDATIONS AND PRACTICES IN PATIENTS WITH TYPE 2 DIABETES: A SURVEY OF HEALTH CARE PROFESSIONALSAND PATIENTS IN THE UK
|
Yurgin, NR
|
|
2006
|
9 |
3 |
p. A37-
1 p.
|
artikel
|
| 219 |
PDB13 COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN ADDING FENOFIBRATE TO TREATMENT WITH A STATIN
|
Sorensen, SV
|
|
2006
|
9 |
3 |
p. A34-A35
nvt p.
|
artikel
|
| 220 |
PDB7 COST IMPACT ASSOCIATED WITH INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS
|
Balkrishnan, R
|
|
2006
|
9 |
3 |
p. A32-A33
nvt p.
|
artikel
|
| 221 |
PDB30 COSTS AND ADHERENCE ASSOCIATED WITH LONG TERM USE OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS
|
Balkrishnan, R
|
|
2006
|
9 |
3 |
p. A40-
1 p.
|
artikel
|
| 222 |
PDB15 COST-UTILITY ANALYSIS OF ANALOG BASAL BOLUS THERAPY AMONG INSULIN-DEPENDENT DIABETES PATIENTS
|
Palmer, A
|
|
2006
|
9 |
3 |
p. A35-
1 p.
|
artikel
|
| 223 |
PDB37/DBI: PATIENT-REPORTED UTILITIES/DISUTILITIES ASSOCIATED WITH TREATMENTS FOR TYPE 2 DIABETES
|
Secnik, K
|
|
2006
|
9 |
3 |
p. A42-
1 p.
|
artikel
|
| 224 |
PDB28 DEVELOPMENT OF NEW INDICES OF GLYCEMIC CONTROL IN PATIENTS WITH DIABETES USING DIGITAL SIGNAL PROCESSING
|
Gold, KF
|
|
2006
|
9 |
3 |
p. A39-
1 p.
|
artikel
|
| 225 |
PDB39 DIABETIC PATIENTS' PREFERENCE FOR INHALED INSULIN
|
Prütz, C
|
|
2006
|
9 |
3 |
p. A43-
1 p.
|
artikel
|
| 226 |
PDB3 EARLY HEALTH TECHNOLOGY ASSESSMENT: CONTINUOUS GLUCOSE MONITORING FOR THE MAINTENANCE OF GLYCEMIC CONTROL IN INSULIN-REQUIRING TYPE I DIABETES
|
Marangos, PJ
|
|
2006
|
9 |
3 |
p. A31-
1 p.
|
artikel
|
| 227 |
PDB18 ECONOMIC BURDEN OF DIABETES ATTRIBUTABLE TO OVERWEIGHT AND OBESITY AMONG U.S. ADULTS
|
Choi, IS
|
|
2006
|
9 |
3 |
p. A36-
1 p.
|
artikel
|
| 228 |
PDB8 ECONOMIC IMPACT OF AUGMENTATION THERAPY IN TYPE 2 DIABETES PATIENTS INITIATED ON SULFONYLUREAS: A RETROSPECTIVE COHORT ANALYSIS
|
Kalsekar, ID
|
|
2006
|
9 |
3 |
p. A33-
1 p.
|
artikel
|
| 229 |
PDB24 EFFECTS OF INDUCING CORRELATION AMONG CHOLESTEROL PARAMETERS ON OUTCOMES IN SIMULATION OF PHARMACEUTICAL EFFECTIVENESS
|
Frick, KD
|
|
2006
|
9 |
3 |
p. A38-
1 p.
|
artikel
|
| 230 |
PDB36 EQ-5D IN TYPE 2 DIABETES: RELATIONSHIPS WITH QUALITY OF LIFE AND COMORBID CONDITIONS
|
Sundaram, M
|
|
2006
|
9 |
3 |
p. A42-
1 p.
|
artikel
|
| 231 |
PDB23 EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL EQUATIONS (UKPDS 68), AND THE UKPDS RISK ENGINE EQUATIONS (UKPDS 56 AND 60) IN FORECASTING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES
|
McEwan, P
|
|
2006
|
9 |
3 |
p. A37-A38
nvt p.
|
artikel
|
| 232 |
PDB6 FACTORS ASSOCIATED WITH DIABETES CONTROL INA LATINO POPULATION USING A HEALTH BEHAVIOR MODEL APPROACH
|
Aranda, GA
|
|
2006
|
9 |
3 |
p. A32-
1 p.
|
artikel
|
| 233 |
PDB34 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS–TYPE I AND TYPE 2
|
Prütz, C
|
|
2006
|
9 |
3 |
p. A41-
1 p.
|
artikel
|
| 234 |
PDB29 IMPACT OF TYPE OF PHARMACY (CHAIN VERSUS INDEPENDENT) ON MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE DATABASE ANALYSIS
|
Sheehan, C
|
|
2006
|
9 |
3 |
p. A39-A40
nvt p.
|
artikel
|
| 235 |
PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY
|
O'Reilly, D
|
|
2006
|
9 |
3 |
p. A36-
1 p.
|
artikel
|
| 236 |
PDB11 LONG-TERM COST-EFFECTIVENESS ANALYSIS OF REPAGLINIDE + METFORMIN VERSUS NATEGLINIDE + METFORMIN IN TYPE 2 DIABETES PATIENTS WITH INADEQUATE GLYCEMIC CONTROL ON MONOTHERAPY: A FINNISH ANALYSIS
|
Valentine, W
|
|
2006
|
9 |
3 |
p. A34-
1 p.
|
artikel
|
| 237 |
PDB25 MARGINAL STRUCTURAL MODELS—AN EXPLANATION AND ILLUSTRATION
|
Gause, D
|
|
2006
|
9 |
3 |
p. A38-
1 p.
|
artikel
|
| 238 |
PDB17 MODELING THE COST-UTILITY OF REDUCED HYPOGLYCEMIA ANDWEIGHT GAIN AMONG TYPE 2 DIABETES PATIENTS NEWLY INITIATED ON BASAL INSULIN: A CASE STUDY OF DETEMIRAND NPH
|
Valentine, W
|
|
2006
|
9 |
3 |
p. A36-
1 p.
|
artikel
|
| 239 |
PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL
|
O'Reilly, D
|
|
2006
|
9 |
3 |
p. A33-A34
nvt p.
|
artikel
|
| 240 |
PDB14 MODELLING THE EFFECTIVENESS OF ORAL AGENTS IN ACHIEVING HBAICAND LIPID TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
Lloyd, AC
|
|
2006
|
9 |
3 |
p. A35-
1 p.
|
artikel
|
| 241 |
PDB5 NEGATIVE PRESSURE WOUND THERAPY ASSOCIATION WITH REDUCED OCCURRENCE OF DIABETIC FOOT ULCER AMPUTATIONS:A RETROSPECTIVE STUDY OF PAYOR CLAIMS DATA
|
Frykberg, RC
|
|
2006
|
9 |
3 |
p. A32-
1 p.
|
artikel
|
| 242 |
PDB9 PHARMACOECONOMIC ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN TYPE II DIABETICS
|
Campbell, HM
|
|
2006
|
9 |
3 |
p. A33-
1 p.
|
artikel
|
| 243 |
PDB22 RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDY WITH PROPENSITY SCORE METHODS: CAN THEIR RESULTS CONVERGE?—A CASE STUDY IN ESTIMATING MARGINAL EFFECT OF INSULIN REGIMENS ON THE REDUCTION OF HEMOGLOBIN AIC AMONG PATIENTS WITH TYPE 2 DIABETES
|
Sun, P
|
|
2006
|
9 |
3 |
p. A37-
1 p.
|
artikel
|
| 244 |
PDB1 RETROSPECTIVE STUDY OF INSULIN GLARGINE USE IN PREVIOUSLY INSULIN-NAIVE U.S. MANAGED CARE PATIENTS WITH TYPE 2 DIABETES
|
Oglesby, AK
|
|
2006
|
9 |
3 |
p. A30-A31
nvt p.
|
artikel
|
| 245 |
PDB33 THE RELATIONSHIP BETWEEN HEALTH RELATED QUALITY OF LIFE (HRQOL)AND PAIN RESPONSE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)
|
McCrink, L
|
|
2006
|
9 |
3 |
p. A41-
1 p.
|
artikel
|
| 246 |
PDB35 TOPIRAMATE TREATMENT IMPROVES QUALITY OF LIFE (QOL)AND NERVE FUNCTION IN PATIENTS WITH DIABETIC NEUROPATHY (DN)
|
Rice, AL
|
|
2006
|
9 |
3 |
p. A41-A42
nvt p.
|
artikel
|
| 247 |
PER1 ECONOMIC EVALUATION OF STRATEGIES FOR SCREENING NEWBORNS FOR BILATERAL HEARING IMPAIRMENT IN FRANCE
|
Barré, S
|
|
2006
|
9 |
3 |
p. A139-A140
nvt p.
|
artikel
|
| 248 |
PER2 OUTCOMES ASSOCIATED WITH AN OTITIS PARENT QUESTIONNAIRE IN PEDIATRIC PATIENTS WITH ACUTE OTITIS MEDIA FOLLOWING ADMINISTRATION OF CEFDINIR ORAL SUSPENSION OR HIGH DOSE AMOXICILLIN/CLAVULANATE ORAL SUSPENSION
|
Schmier, JK
|
|
2006
|
9 |
3 |
p. A140-
1 p.
|
artikel
|
| 249 |
PEY8 ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA
|
Vicente, C
|
|
2006
|
9 |
3 |
p. A142-
1 p.
|
artikel
|
| 250 |
PEY5 ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY (VISUDYNE®) COMPARED TO USUAL CARE IN THE TREATMENT OF AGE RELATED MACULAR DEGENERATION (ARMD) IN USA
|
Barry, SJ
|
|
2006
|
9 |
3 |
p. A141-A142
nvt p.
|
artikel
|
| 251 |
PEY4 EVALUATION OF DIRECT MEDICAL COST OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN PATIENTS IN THE MEDICARE POPULATION
|
Zhou, Z
|
|
2006
|
9 |
3 |
p. A141-
1 p.
|
artikel
|
| 252 |
PEY2 PREVALENCE AND DESCRIPTION OF TREATMENT WITH INTRAOCULAR PRESSURE LOWERING TOPICAL MEDICATIONS IN CONTINENTAL FRANCE
|
Delcout, C
|
|
2006
|
9 |
3 |
p. A140-A141
nvt p.
|
artikel
|
| 253 |
PEY1 PREVALENCE OF INTRAOCULAR HYPERTENSION AND GLAUCOMA IN AN UNSELECTED FRENCH POPULATION
|
Bron, A
|
|
2006
|
9 |
3 |
p. A140-
1 p.
|
artikel
|
| 254 |
PEY6 REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE
|
Chiang, TH
|
|
2006
|
9 |
3 |
p. A142-
1 p.
|
artikel
|
| 255 |
PEY3 THE ECONOMIC IMPACT OF BLUE-LIGHT FILTERING INTRAOCULAR LENSES ON AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH CATARACT SURGERY
|
Reddy, P
|
|
2006
|
9 |
3 |
p. A141-
1 p.
|
artikel
|
| 256 |
PEY7 VARIATIONS IN PHYSICIAN PRESCRIBING OF TOPICAL MEDICATIONS FOR GLAUCOMA IN US OUTPATIENT SETTINGS
|
Bhosle, MJ
|
|
2006
|
9 |
3 |
p. A142-
1 p.
|
artikel
|
| 257 |
PG18 A COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR ESOPHAGEAL VARICES: HOW GOOD DOES A CLINICAL DECISION AID HAVE TO BE?
|
Klein, RW
|
|
2006
|
9 |
3 |
p. A45-
1 p.
|
artikel
|
| 258 |
PG14 COMPARATIVE EFFICACY OF LAMIVUDINE WITH ADEFOVIR IN PATIENTS WITH HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B: DIRECT AND INDIRECT META-ANALYSIS
|
Sun, X
|
|
2006
|
9 |
3 |
p. A44-
1 p.
|
artikel
|
| 259 |
PG15 COMPARING THE COST-EFFECTIVENESS OF THE INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV): A MODEL EVALUATING THE CLINICAL AND ECONOMIC IMPACT OF CURRENT TREATMENT OPTIONS
|
Goldberg, LD
|
|
2006
|
9 |
3 |
p. A44-A45
nvt p.
|
artikel
|
| 260 |
PG17 COST-EFFECTIVENESS (C-E) OFTEGASEROD VS. PLACEBO FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
|
Akehurst, RL
|
|
2006
|
9 |
3 |
p. A45-
1 p.
|
artikel
|
| 261 |
PG16 COST-EFFECTIVENESS OF SCREENING PRISON POPULATION OF MARYLAND CORRECTIONAL FACILITIES FOR HEPATITIS C
|
Shaya, FT
|
|
2006
|
9 |
3 |
p. A45-
1 p.
|
artikel
|
| 262 |
PG19 COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH CHRONIC HEPATITIS C
|
Tarn, YH
|
|
2006
|
9 |
3 |
p. A46-
1 p.
|
artikel
|
| 263 |
PG12 DOSE-RESPONSE RELATION OF INTERFERON-ALPHA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B: META-ANALYSIS AND META-REGRESSION OF RANDOMIZED TRIALS
|
Sun, X
|
|
2006
|
9 |
3 |
p. A43-A44
nvt p.
|
artikel
|
| 264 |
PG11 HEPATITIS B IMMUNISATION FOR NEWBORNS OF HEPATITIS B SURFACE ANTIGEN-POSTITIVE MOTHERS: A COCHRANE HEPATO-BILIARY GROUP SYSTEMATIC REVIEW AND META-ANALYSIS
|
Lee, CF
|
|
2006
|
9 |
3 |
p. A43-
1 p.
|
artikel
|
| 265 |
PGI13 A COST UTILITY ANALYSIS OF PEGUINTERFERON ALFA 2B (I2KD) (PEG2B)VERSUS PEGUINTERFERON ALFA 2A (40KD) (PEG2A) FOR THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN BRAZIL
|
Fonseca, M
|
|
2006
|
9 |
3 |
p. A47-
1 p.
|
artikel
|
| 266 |
PGI21 ADHERENCE AND RIBAVIRIN DOSE AS CRITICAL SUCCESS FACTORS TO THE CHRONIC HEPATITIS C (CHC) TREATMENT: A CROSS SECTIONAL EVALUATION IN BRAZIL
|
Araujo, G
|
|
2006
|
9 |
3 |
p. A49-
1 p.
|
artikel
|
| 267 |
PGI18 A NEW APPROACH TO USING SELF-REPORTED UTILIZATION TO ESTIMATE COST ASSOCIATED WITH MILD, MODERATE, AND SEVERE GERD-RELATED SYMPTOMS
|
Doan, OV
|
|
2006
|
9 |
3 |
p. A48-A49
nvt p.
|
artikel
|
| 268 |
PGI10 COST OF ILLNESS IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE
|
Brook, R
|
|
2006
|
9 |
3 |
p. A46-
1 p.
|
artikel
|
| 269 |
PGI12 COST-UTILITY ANALYSIS OFTEGASEROD FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME
|
Chen, SY
|
|
2006
|
9 |
3 |
p. A46-A47
nvt p.
|
artikel
|
| 270 |
PGI14 COST-UTILITY OF A MODALITY OF “C” VIRUS HEPATITIS TREATMENT IN PATIENTS THAT DO NOT RESPOND TO INTERFERON PLUS RIBAVIRIN IN MEXICO
|
Nevarez-Sida, A
|
|
2006
|
9 |
3 |
p. A47-
1 p.
|
artikel
|
| 271 |
PGI11 ECONOMIC BURDEN OF ENDOSCOPY-RELATED INFECTIONS, PSEUDO-INFECTIONS AND TOXIC REACTIONS
|
Seoane-Vazquez, E
|
|
2006
|
9 |
3 |
p. A46-
1 p.
|
artikel
|
| 272 |
PGI19 OBJECTIVE MEASUREMENT OF PRODUCTIVITY WHILE AT WORK IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE
|
Wahlqvist, P
|
|
2006
|
9 |
3 |
p. A49-
1 p.
|
artikel
|
| 273 |
PGI15 PRIOR AUTHORIZATION AND THE APPROPRIATE PRESCRIBING OF TEGASEROD: A LOOK AT A MANAGED CARE POPULATION
|
Margolis, J
|
|
2006
|
9 |
3 |
p. A47-A48
nvt p.
|
artikel
|
| 274 |
PGI20 SUBJECTIVE REASONS FOR NONCOMPLIANCE WITH MEDICATION REGIMEN IN INFLAMMATORY BOWEL DISEASE PATIENTS
|
Lapshin, O
|
|
2006
|
9 |
3 |
p. A49-
1 p.
|
artikel
|
| 275 |
PGI17 TRENDS IN AMBULATORY CARE UTILIZATION FOR CONSTIPATION AND IRRITABLE BOWEL SYNDROME: 1993-2003
|
Karve, SJ
|
|
2006
|
9 |
3 |
p. A48-
1 p.
|
artikel
|
| 276 |
PGI16 TRENDS OF GASTRIC ACID-SUPPRESSIVE DRUG USE IN THE GENERAL PRACTICE OF UK FROM 1995 TO 2005
|
Fan, T
|
|
2006
|
9 |
3 |
p. A48-
1 p.
|
artikel
|
| 277 |
PGI22 WEIGHING TREATMENT BENEFITS AGAINST TREATMENT RISKS: CROHN'S DISEASE PATIENTS'WILLINGNESS TO ACCEPT RISK-BENEFIT TRADEOFFS
|
Johnson, FR
|
|
2006
|
9 |
3 |
p. A50-
1 p.
|
artikel
|
| 278 |
PG13 MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN
|
Wang, J
|
|
2006
|
9 |
3 |
p. A44-
1 p.
|
artikel
|
| 279 |
PHM1 COST-EFFECTIVENESS OF ONCE-DAILY ORAL CHELATION THERAPY WITH DEFERASIROX VERSUS INFUSIONAL DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS
|
Delea, T
|
|
2006
|
9 |
3 |
p. A143-
1 p.
|
artikel
|
| 280 |
PHM4 COSTS AND CONSEQUENCES OF INADEQUATE COMPLIANCE WITH DEFEROXAMINE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA
|
Delea, T
|
|
2006
|
9 |
3 |
p. A144-
1 p.
|
artikel
|
| 281 |
PHM3 ECONOMIC ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE HOME TREATMENT OF MINOR-TO-MODERATE BLEEDS IN HEMOPHILIA PATIENTS WITH INHIBITORS: A U.S. COST-OF-BLEED MODEL
|
Stephens, JM
|
|
2006
|
9 |
3 |
p. A143-A144
nvt p.
|
artikel
|
| 282 |
PHM2 ECONOMIC AND QUALITY OF LIFE BURDEN OF HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA
|
Tran, KT
|
|
2006
|
9 |
3 |
p. A143-
1 p.
|
artikel
|
| 283 |
PHM5 PILOT STUDYTO ESTABLISH PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES USED TO TREAT HAEMOPHILIC PATIENTS WITH INHIBITORS
|
Scalone, L
|
|
2006
|
9 |
3 |
p. A144-
1 p.
|
artikel
|
| 284 |
PHP1 A COMPARISON OF CLINICAL TRIAL PARTICIPANTS TO THE GENERAL PATIENT POPULATION
|
Bolge, SC
|
|
2006
|
9 |
3 |
p. A144-A145
nvt p.
|
artikel
|
| 285 |
PHP6 BENEFICIARIES' OUT-OF-POCKET COSTS UNDER THE MEDICARE PRESCRIPTION DRUG BENEFIT: EVIDENCE FROM MEDICARE DISCOUNT DRUG CARD CLAIMS DATA
|
Esposito, D
|
|
2006
|
9 |
3 |
p. A146-
1 p.
|
artikel
|
| 286 |
PHP8 BRITISH COLUMBIAN PHYSICIANS' OPINIONS REGARDING REFERENCE DRUG AND GENERIC SUBSTITUTION PROGRAMS
|
Polinski, J
|
|
2006
|
9 |
3 |
p. A146-A147
nvt p.
|
artikel
|
| 287 |
PHP21 CALCULATION OF LORENZ CONCENTRATION CURVES AND GINI COEFFICIENT OF HEALTH EXPENDITURES IN HUNGARY
|
Boncz, I
|
|
2006
|
9 |
3 |
p. A150-A151
nvt p.
|
artikel
|
| 288 |
PHP10 CHARACTERISTICS OF SENIORS WITH HIGH ANNUAL PRESCRIPTION DRUG EXPENDITURES: FINDINGS FROM THE 2002 AND 2003 MEDICAL EXPENDITURE PANEL SURVEY
|
Daniel, GW
|
|
2006
|
9 |
3 |
p. A147-
1 p.
|
artikel
|
| 289 |
PHP27 CLUSTER ANALYSIS OF STATE MEDICAID PROGRAMS
|
Roy, S
|
|
2006
|
9 |
3 |
p. A152-
1 p.
|
artikel
|
| 290 |
PHP19 COST SAVINGS ASSOCIATED WITH TABLET SPLITTING PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING
|
Gomes, JP
|
|
2006
|
9 |
3 |
p. A150-
1 p.
|
artikel
|
| 291 |
PHP26 DEVELOPING A MEASURE OF PATIENT EMPOWERMENT TO BE APPLIED IN THE GENERAL COMMUNITY
|
Loukanova, S
|
|
2006
|
9 |
3 |
p. A152-
1 p.
|
artikel
|
| 292 |
PHP23 EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS: AN EMPIRICAL ANALYSIS
|
Chen, CC
|
|
2006
|
9 |
3 |
p. A151-
1 p.
|
artikel
|
| 293 |
PHP24 ELECTRONIC INTERFACES FOR SHARING PATIENT DATA: ESTIMATING RETURN ON INVESTMENT IN HOSPICE
|
Mondgock, D
|
|
2006
|
9 |
3 |
p. A151-
1 p.
|
artikel
|
| 294 |
PHP13 ENHANCING THE SAFETY OF OTC MEDICATION USE FOR HISPANIC CONSUMERS WITH BILINGUAL LABELS
|
Sansgiry, S
|
|
2006
|
9 |
3 |
p. A148-
1 p.
|
artikel
|
| 295 |
PHP25 HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PHARMACEUTICAL CARE: EVALUATING PHARMACIST'S KNOWLEDGE, UNDERSTANDING AND PERCEIVED BARRIERS IN PHARMACY PRACTICE
|
Chandak, P
|
|
2006
|
9 |
3 |
p. A152-
1 p.
|
artikel
|
| 296 |
PHP3 IMPACT OF CONSUMER-DIRECTED HEALTH PLAN ON PHARMACY UTILIZATION
|
Moore, J
|
|
2006
|
9 |
3 |
p. A145-
1 p.
|
artikel
|
| 297 |
PHP17 IMPACT OF CO-PAY DIFFERENTIAL ON GENERIC PRESCRIPTIONS FILLED THROUGH 90-DAY RETAIL CHANNEL
|
Jiang, JZ
|
|
2006
|
9 |
3 |
p. A149-
1 p.
|
artikel
|
| 298 |
PHP18 IMPACT OF STEPS (SAFE, THERAPEUTIC AND ECONOMIC PHARMACEUTICAL SELECTION) MODEL ON PRESCRIBING COSTS OF STATINS
|
Alabbadi, I
|
|
2006
|
9 |
3 |
p. A149-A150
nvt p.
|
artikel
|
| 299 |
PHP20 ISPOR CONTRIBUTED RESEARCH 1998-2005: EVALUATION OF TRENDS & QUALITY INDICATORS
|
Smith, MD
|
|
2006
|
9 |
3 |
p. A150-
1 p.
|
artikel
|
| 300 |
PHP12 MEDICINE PRICES, AVAILABILITY AND AFFORDABILITY IN RAJASTHAN, INDIA
|
Kotwani, A
|
|
2006
|
9 |
3 |
p. A148-
1 p.
|
artikel
|
| 301 |
PHP2 MEMBERS INITIAL EXPERIENCE WITH A CONSUMER-DRIVEN PHARMACY BENEFIT PLAN DESIGN
|
Gams, EL
|
|
2006
|
9 |
3 |
p. A145-
1 p.
|
artikel
|
| 302 |
PHP4 OUT-OF-POCKET PRICE OF OUTPATIENT MEDICATIONS IN THE UNITED STATES
|
Craig, B
|
|
2006
|
9 |
3 |
p. A145-
1 p.
|
artikel
|
| 303 |
PHP22 PRESCRIPTION DRUG PRICE COMPARISONS BETWEEN CANADIAN AND US ON-LINE PHARMACIES OVER A SIX-MONTH PERIOD
|
Richards, KM
|
|
2006
|
9 |
3 |
p. A151-
1 p.
|
artikel
|
| 304 |
PHP11 PRESCRIPTION PATTERNS OF POTENTIALLY INAPPROPRIATE MEDICATIONS AMONG OLDER MEDICARE MANAGED CARE BENEFICIARIES
|
Bonnet, PC
|
|
2006
|
9 |
3 |
p. A147-A148
nvt p.
|
artikel
|
| 305 |
PHP9 SUMMARY OF THE FIRST YEAR OF A DISEASE MANAGEMENT PROGRAM IN PATIENTS WITH BLEEDING DISORDERS
|
Tencer, T
|
|
2006
|
9 |
3 |
p. A147-
1 p.
|
artikel
|
| 306 |
PHP15 THE CORRELATION OF SATISFACTION OF MEDICARE BENEFICIARIES WITH ACCESS AND QUALITY OF CARE
|
Créa, JE
|
|
2006
|
9 |
3 |
p. A148-A149
nvt p.
|
artikel
|
| 307 |
PHP7 THE DECISION TO CONDUCT A HEAD-TO-HEAD COMPARATIVE TRIAL: A GAME-THEORETIC ANALYSIS
|
Mansley, EC
|
|
2006
|
9 |
3 |
p. A146-
1 p.
|
artikel
|
| 308 |
PHP28 THE EFFECT OF HIGH-RISK MEDICATIONS ON VISIT TIME WITH PHYSICIANS: RESULTS FROM THE NAMCS SURVEY
|
John, El
|
|
2006
|
9 |
3 |
p. A152-A153
nvt p.
|
artikel
|
| 309 |
PHP16 THE IMPACT OF THE PHARMACY AND THERAPEUTICS COMMITTEE ON THE PATIENTS'ACCESS TO PRESCRIPTION DRUGS IN THE SAUDI MINISTRY OF HEALTH: EXPLORATORY AND COMPARISON STUDY
|
Alkelya, MA
|
|
2006
|
9 |
3 |
p. A149-
1 p.
|
artikel
|
| 310 |
PIH2 A COST EFFECTIVENESS STUDY OF CARBETOCINE COMPARED TO OXYTOCIN FORTHE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS
|
Del-Angel-Garcia, G
|
|
2006
|
9 |
3 |
p. A50-
1 p.
|
artikel
|
| 311 |
PIH7 APPROPRIATE MEDICATION PRESCRIBING FORTHE ELDERLY: PHYSICIAN CONFIDENCE AND KNOWLEDGE
|
Talati, AR
|
|
2006
|
9 |
3 |
p. A52-
1 p.
|
artikel
|
| 312 |
PIH5 A SYSTEMATIC REVIEW OF ATROPHIC VAGINITIS TREATMENT, DURATION OF THERAPY, AND HEALTH CARE COSTS
|
Balu, S
|
|
2006
|
9 |
3 |
p. A51-
1 p.
|
artikel
|
| 313 |
PIH15 BARRIERS TO COMMUNICATION ABOUT ERECTILE DYSFUNCTION IN PATIENTS TAKING ANTIHYPERTENSIVE MEDICATIONS
|
Harriett, J
|
|
2006
|
9 |
3 |
p. A54-A55
nvt p.
|
artikel
|
| 314 |
PIH13 COMPLIANCE WITH PRESCRIBED ONCE A DAY PLACEBO IN ADOLESCENT HEALTHYVOLUNTEERS
|
Vander Stichele, R
|
|
2006
|
9 |
3 |
p. A54-
1 p.
|
artikel
|
| 315 |
PIH3 COST-EFFECTIVENESS ANALYSIS OF ORAL PHARMACOLOGICAL TREATMENTS OF ERECTILE DYSFUNCTION
|
Roy, S
|
|
2006
|
9 |
3 |
p. A51-
1 p.
|
artikel
|
| 316 |
PIH11 DEVELOPMENT AND VALIDATION OF THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY
|
Wallenstein, GV
|
|
2006
|
9 |
3 |
p. A53-
1 p.
|
artikel
|
| 317 |
PIH17 DEVELOPMENT OF A PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE FOR BENIGN PROSTATIC HYPERPLASIA (BPH-PSTQ)
|
Barron, R
|
|
2006
|
9 |
3 |
p. A55-
1 p.
|
artikel
|
| 318 |
PIH4 ECONOMIC BURDEN OF ABNORMAL UTERINE BLEEDING: ARE THERE PIECES MISSING?
|
Liu, Z
|
|
2006
|
9 |
3 |
p. A51-
1 p.
|
artikel
|
| 319 |
PIH18 EXPLORATORY FACTOR ANALYSIS OF A 13 ITEM BPH PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE (BPH-PSTQ)
|
Barron, R
|
|
2006
|
9 |
3 |
p. A55-
1 p.
|
artikel
|
| 320 |
PIH6 MEDICAL RESOURCE UTILIZATION IN DIAGNOSED PREMATURE EJACULATION PATIENTS
|
Nuyts, G
|
|
2006
|
9 |
3 |
p. A51-A52
nvt p.
|
artikel
|
| 321 |
PIH14 RECALL PERIODS FOR SATISFACTION WITH SEXUAL INTERCOURSE: TWO APPROACHES FOR ASSESSING OUTCOMES
|
Rothman, M
|
|
2006
|
9 |
3 |
p. A54-
1 p.
|
artikel
|
| 322 |
PIH12 SURVEY ASSESSMENT OF TREATMENT COMPLIANCE AND MEDICATION TAKING BEHAVIOR IN BENIGN PROSTATIC HYPERPLASIA
|
Campbell, U
|
|
2006
|
9 |
3 |
p. A53-A54
nvt p.
|
artikel
|
| 323 |
PIH9 TEXAS COMMUNITY PHARMACISTS'WILLINGNESS TO ACCEPT PHARMACIST INITIATED EMERGENCY CONTRACEPTION
|
Griggs, SK
|
|
2006
|
9 |
3 |
p. A52-A53
nvt p.
|
artikel
|
| 324 |
PIH1 THE EXCESS PREVALENCE OF COMORBIDITIES ASSOCIATED WITH ERECTILE DYSFUNCTION IN A LARGE STATE MEDICAID PROGRAM
|
Boulanger, L
|
|
2006
|
9 |
3 |
p. A50-
1 p.
|
artikel
|
| 325 |
PIH10 THE TRANSLATION AND CULTURAL ADAPTATION OF AN ADOLESCENT SEXUAL BEHAVIOUR QUESTIONNAIRE
|
Reaney, MD
|
|
2006
|
9 |
3 |
p. A53-
1 p.
|
artikel
|
| 326 |
PIH16 WHAT EXPECTATIONS DO MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH) HAVE FOR TREATMENT?
|
Kotak, S
|
|
2006
|
9 |
3 |
p. A55-
1 p.
|
artikel
|
| 327 |
PIN17 A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM
|
Yeh, WS
|
|
2006
|
9 |
3 |
p. A158-
1 p.
|
artikel
|
| 328 |
PIN19 A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOMES IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL
|
Sakalis, E
|
|
2006
|
9 |
3 |
p. A159-
1 p.
|
artikel
|
| 329 |
PIN23 A REVIEW OF HERD EFFECTS IN THE ECONOMIC EVALUATION OF CHILDHOOD VACCINATIONS
|
Vicente, C
|
|
2006
|
9 |
3 |
p. A160-
1 p.
|
artikel
|
| 330 |
PIN16 CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN ACUTE HOSPITALS: A PREVALENT COST ISSUE
|
O'Brien, JA
|
|
2006
|
9 |
3 |
p. A158-
1 p.
|
artikel
|
| 331 |
PIN20 COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE
|
Frei, CR
|
|
2006
|
9 |
3 |
p. A159-
1 p.
|
artikel
|
| 332 |
PIN2 COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS: INFORMATION FROM THE SIDESTEP STUDY
|
Turpin, RS
|
|
2006
|
9 |
3 |
p. A153-A154
nvt p.
|
artikel
|
| 333 |
PIN5 COST EFFECTIVENESS OF ADDING 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE TO A CHILDHOOD VACCINATION—IMPACT OF HERD IMMUNITY
|
Kristiansen, IS
|
|
2006
|
9 |
3 |
p. A154-A155
nvt p.
|
artikel
|
| 334 |
PIN8 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA IN ARGENTINA
|
Aiello, EC
|
|
2006
|
9 |
3 |
p. A155-A156
nvt p.
|
artikel
|
| 335 |
PIN10 COST EFFECTIVENESS OFTIPRANAVIR IN TREATMENT-EXPERIENCED HIV PATIENTS IN THE USA
|
Simpson, KN
|
|
2006
|
9 |
3 |
p. A156-
1 p.
|
artikel
|
| 336 |
PIN6 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS AMPHOTERICIN B DEOXICOLATE FOR THE PRIMARY TREATMENT OF INVASIVE ASPERGILLOSIS
|
Aiello, EC
|
|
2006
|
9 |
3 |
p. A155-
1 p.
|
artikel
|
| 337 |
PIN13 COST OF THERAPY OF UPPER RESPIRATORY TRACT INFECTIONS IN A DEPRESSED ECONOMY
|
Suleiman, IA
|
|
2006
|
9 |
3 |
p. A157-
1 p.
|
artikel
|
| 338 |
PIN14 DIRECT MEDICAL COSTS OF PATIENTS WITH HIV/AIDS IN MEXICO
|
Contreras-Hernandez, I
|
|
2006
|
9 |
3 |
p. A157-A158
nvt p.
|
artikel
|
| 339 |
PIN4 ECONOMIC ANALYSIS OF LATENT TUBERCULOSIS INFECTION (LTBI) SCREENING IN MILITARY RECRUITS: QUANTIFERON®-TB GOLD IN-TUBE (QFT-GIT) VERSUS TUBERCULIN SKIN TESTING (TST)
|
Nevin, R
|
|
2006
|
9 |
3 |
p. A154-
1 p.
|
artikel
|
| 340 |
PIN9 ECONOMIC EVALUATION FORTHE ANTIMICROBIAL EMPIRIC TREATMENT OF HOSPITALIZED PATIENTS WITH VENTILATOR—ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS IN MEXICO
|
Contreras-Hernandez, I
|
|
2006
|
9 |
3 |
p. A156-
1 p.
|
artikel
|
| 341 |
PIN1 HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS INFECTION:A META-ANALYSIS
|
Ghosh, S
|
|
2006
|
9 |
3 |
p. A153-
1 p.
|
artikel
|
| 342 |
PIN18 HOSPITAL LENGTH-OF-STAYAND COSTS ASSOCIATED WITH USE AND EARLIER INITIATION OF DROTRECOGIN ALFA (ACTIVATED) IN ADULT PATIENTS WITH THE HIGHEST PROPENSITY OF HAVING SEVERE SEPSIS
|
Ernst, FR
|
|
2006
|
9 |
3 |
p. A159-
1 p.
|
artikel
|
| 343 |
PIN12 LIFETIME MEDICAL COST OF CHRONIC HEPATITIS B
|
Miriti, M'Kiaira K
|
|
2006
|
9 |
3 |
p. A157-
1 p.
|
artikel
|
| 344 |
PIN3 THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C: THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN
|
Cross, JT
|
|
2006
|
9 |
3 |
p. A154-
1 p.
|
artikel
|
| 345 |
PIN15 THE EXPECTED ECONOMIC BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI)
|
Mallick, R
|
|
2006
|
9 |
3 |
p. A158-
1 p.
|
artikel
|
| 346 |
PIN11 THE IMPACT OF MECHANICAL VENTILATION ON OUTCOMES AND COSTS IN NOSOCOMIAL PNEUMONIA
|
Neslusan, C
|
|
2006
|
9 |
3 |
p. A156-A157
nvt p.
|
artikel
|
| 347 |
PIN21 USE OF EVIDENCE BASED MODELS TO DEMONSTRATE THE LONG-TERM CLINICAL BENEFITS OF HPV VACCINATION
|
Bernard, L
|
|
2006
|
9 |
3 |
p. A160-
1 p.
|
artikel
|
| 348 |
PIN22 USE OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING WITH MONTE CARLO SIMULATION TO REDUCE ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING PREDICTED EFFICACY
|
Frei, CR
|
|
2006
|
9 |
3 |
p. A160-
1 p.
|
artikel
|
| 349 |
PMC20 A BAYESIAN APPROACH TO PREDICT EFFECTIVENESS OF NEWLY INTRODUCED DRUGS IN DAILY PRACTICE BASED ON THE RELATION BETWEEN EFFICACY AND EFFECTIVENESS OF COMPETING INTERVENTIONS
|
Jansen, JP
|
|
2006
|
9 |
3 |
p. A62-
1 p.
|
artikel
|
| 350 |
PMC22 ALLOCATION OF PRESCRIPTION DATA BY INDICATION: A METHODOLOGY INTEGRATING COMPLEMENTARY PATIENT-LEVEL INFORMATION SOURCES
|
Henderson, SC
|
|
2006
|
9 |
3 |
p. A62-
1 p.
|
artikel
|
| 351 |
PMC8 AN INTERACTIVE ECONOMIC MODEL FOR VACUUM ASSISTED CLOSURE THERAPY
|
Williams, DV
|
|
2006
|
9 |
3 |
p. A58-
1 p.
|
artikel
|
| 352 |
PMC13 APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY
|
Zhang, XH
|
|
2006
|
9 |
3 |
p. A59-A60
nvt p.
|
artikel
|
| 353 |
PMC5 ARE NON-INFERIORITY TRIALS SUITABLE FOR ECONOMIC EVALUATION? ESTIMATION IS STILL MORE IMPORTANT THAN HYPOTHESIS TESTING
|
Briggs, A
|
|
2006
|
9 |
3 |
p. A57-
1 p.
|
artikel
|
| 354 |
PMC7 A STANDARDIZED METHODOLOGYTO MEASURE MEDICINE PRICES, AVAILABILITY, AFFORDABILITY AND PRICE COMPONENTS IN DEVELOPING AND TRANSITIONAL COUNTRIES
|
Kotwani, A
|
|
2006
|
9 |
3 |
p. A57-A58
nvt p.
|
artikel
|
| 355 |
PMC24 BAYESIAN ESTIMATION OF COST-EFFECTIVENESS ADJUSTED FOR REAL WORLD CONSIDERING STATISTICAL ERRORS IN CLINICAL TRIALS
|
Moriwaki, K
|
|
2006
|
9 |
3 |
p. A63-
1 p.
|
artikel
|
| 356 |
PMC26 CONVERTING SF-36 INTO EQ-5D: DESIGNED TO SUCCEED OR CALCULATED TO FAIL?
|
Chuang, LH
|
|
2006
|
9 |
3 |
p. A63-A64
nvt p.
|
artikel
|
| 357 |
PMC21 DEVELOPMENT AND VALIDATION OF A SCALE TO MEASURE PATIENTS'TRUST IN PHARMACISTS IN SINGAPORE
|
Zhang, XH
|
|
2006
|
9 |
3 |
p. A62-
1 p.
|
artikel
|
| 358 |
PMC11 DEVELOPMENT OF A GLOBAL HEALTH ECONOMIC MODEL OF THE NATURAL HISTORY OF HPV INFECTION AND CERVICAL CANCER: CALIBRATION TO THE UNITED KINGDOM AND NETHERLANDS
|
Ferko, N
|
|
2006
|
9 |
3 |
p. A59-
1 p.
|
artikel
|
| 359 |
PMC19 EVALUATING THE STRENGTH OF EVIDENCE OF CHANGE: A QUALIFIED CHANGE VS SIMPLE DIFFERENCE APPROACH TO QUALITY OF LIFE RATINGS
|
Tractenberg, RE
|
|
2006
|
9 |
3 |
p. A61-
1 p.
|
artikel
|
| 360 |
PMC16 GENERAL HEALTH STATUS AND PATIENT SATISFACTION: ARE THEY MUTUALLY EXCLUSIVE OR CORRELATED OUTCOMES?
|
Sansgiry, S
|
|
2006
|
9 |
3 |
p. A60-A61
nvt p.
|
artikel
|
| 361 |
PMC2 HEALTH CONDITIONS IN POSTMENOPAUSAL WOMEN AND IMPLICATIONS FOR THE DESIGN OF CLINICAL TRIALS OF AROMATASE INHIBITORS
|
Zhang, D
|
|
2006
|
9 |
3 |
p. A56-
1 p.
|
artikel
|
| 362 |
PMC3 HOW MUCH DOES A DAY IN THE HOSPITAL COSTÏ
|
Candrilli, S
|
|
2006
|
9 |
3 |
p. A56-
1 p.
|
artikel
|
| 363 |
PMC15 INTERNET-BASED UTILITY ELICITATION OF A GENERIC HEALTH STATE
|
Livengood, K
|
|
2006
|
9 |
3 |
p. A60-
1 p.
|
artikel
|
| 364 |
PMC25 MEASURING SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES: NEW SOLUTIONS TO OLD PROBLEMS
|
Kind, P
|
|
2006
|
9 |
3 |
p. A63-
1 p.
|
artikel
|
| 365 |
PMC17 MULTI-METHOD QUALITATIVE APPROACH TO DEVELOP COMPREHENSIVE PATIENT-REPORTED OUTCOME MEASURES: AN EXAMPLE FROM DENTAL CARE
|
Keller, S
|
|
2006
|
9 |
3 |
p. A61-
1 p.
|
artikel
|
| 366 |
PMC23 NOT ALL PATIENTS ARE AVERAGE:THE IMPORTANCE OF RECOGNISING PATIENT HETEROGENEITY
|
Van Staa, TP
|
|
2006
|
9 |
3 |
p. A63-
1 p.
|
artikel
|
| 367 |
PMC14 PREVAILING JUDGMENTS ABOUT SOCIETY'S WILLINGNESS TO PAY FORA QALY: DO THEY VARY BY COUNTRY? HAVE THEY CHANGED OVERTIME?
|
Greenberg, D
|
|
2006
|
9 |
3 |
p. A60-
1 p.
|
artikel
|
| 368 |
PMC12 THE COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS: A STRUCTURED REVIEW OF THE LITERATURE
|
Fleurence, R
|
|
2006
|
9 |
3 |
p. A59-
1 p.
|
artikel
|
| 369 |
PMC4 THE LEVEL OF AWARENESS OFTMC PHYSICIANS ON THE PRICES OF COMMONLY PRESCRIBED MEDICATIONS AND DIAGNOSTIC PROCEDURES AND ITS EFFECT ON THEIR PRESCRIBING PREFERENCES
|
The, JJA
|
|
2006
|
9 |
3 |
p. A56-A57
nvt p.
|
artikel
|
| 370 |
PMC18 THE PROLABELS DATABASE: A NEW ON-LINE TOOL TO EXPLORE THE WORDING AND TYPES OF PRO INCLUDED IN APPROVED MEDICINAL PRODUCTS LABELS
|
Caron, M
|
|
2006
|
9 |
3 |
p. A61-
1 p.
|
artikel
|
| 371 |
PMC9 THE USE OF QUINTILE ANALYSIS ASA MEASURE OF DISEASE SEVERITY: A COMPARISON WITHIN AND ACROSS DISEASES
|
Brook, R
|
|
2006
|
9 |
3 |
p. A58-
1 p.
|
artikel
|
| 372 |
PMC10 THE US NATIONAL VIOLENT DEATH REPORTING SYSTEM (NVDRS) AS A MODEL OF A NATIONAL PUBLIC HEALTH REGISTRY
|
Lipskiy, N
|
|
2006
|
9 |
3 |
p. A58-A59
nvt p.
|
artikel
|
| 373 |
PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?
|
Goeree, RA
|
|
2006
|
9 |
3 |
p. A56-
1 p.
|
artikel
|
| 374 |
PMH11 A COST-EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CHRONIC SCHIZOPHRENIA IN MEXICO
|
Mould, J
|
|
2006
|
9 |
3 |
p. A67-
1 p.
|
artikel
|
| 375 |
PMH38 ADHERENCE LEVELS AND DIFFERENTIAL USE OF MENTAL HEALTH SERVICES IN THE TREATMENT OF SCHIZOPHRENIA
|
Thomas, NA
|
|
2006
|
9 |
3 |
p. A76-
1 p.
|
artikel
|
| 376 |
PMH18 ANALYZING PATTERNS OF ANTIDEPRESSANT USE AND THE COST CONSEQUENCES OF PRODUCT SWITCHING
|
Kruzikas, D
|
|
2006
|
9 |
3 |
p. A69-
1 p.
|
artikel
|
| 377 |
PMH13 AN ECONOMIC COST ANALYSIS OF ATYPICAL ANTIPSYCHOTIC SINGLE TREATMENT FOR BIPOLAR DISORDER IN A MEDICAID PROGRAM
|
Liu, GG
|
|
2006
|
9 |
3 |
p. A68-
1 p.
|
artikel
|
| 378 |
PMH12 AN ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTIC FOR BIPOLAR DISORDER IN THE NC MEDICAID PROGRAM
|
Liu, GG
|
|
2006
|
9 |
3 |
p. A67-A68
nvt p.
|
artikel
|
| 379 |
PMH7 ANNUAL COSTS ASSOCIATED WITH PATTERNS OF ANTIDEPRESSANT TREATMENT RESPONSE AMONG EMPLOYEES
|
Wu, E
|
|
2006
|
9 |
3 |
p. A66-
1 p.
|
artikel
|
| 380 |
PMH19 ANTIPSYCHOTIC NON-ADHERENCE AND COSTS OF SHORT-TERM INPATIENT TREATMENT FOR SCHIZOPHRENIA
|
Olfson, M
|
|
2006
|
9 |
3 |
p. A70-
1 p.
|
artikel
|
| 381 |
PMH22 ANTIPSYCHOTIC POLYPHARMACY COSTS:A FIVE-STATE MEDICAID STUDY
|
Valuck, RJ
|
|
2006
|
9 |
3 |
p. A70-A71
nvt p.
|
artikel
|
| 382 |
PMH32 ANTIPSYCHOTIC THERAPY IN PATIENTS WITH BIPOLAR DISORDER: EFFECTS ON TOTAL AND MENTAL HEALTH CARE COSTS
|
Hassan, M
|
|
2006
|
9 |
3 |
p. A74-
1 p.
|
artikel
|
| 383 |
PMH29 ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATION CLINICAL PRIOR AUTHORIZATION PROGRAM'S IMPACT ON PRESCRIPTION DRUG UTILIZATION AND COSTS
|
Sun, SX
|
|
2006
|
9 |
3 |
p. A73-
1 p.
|
artikel
|
| 384 |
PMH40 ATYPICAL ANTIPSYCHOTIC COMPLIANCE AND PERSISTENCE AND ASSOCIATED HEALTH CARE UTILIZATION IN THE TREATMENT OF SCHIZOPHRENIA
|
Sun, SX
|
|
2006
|
9 |
3 |
p. A76-A77
nvt p.
|
artikel
|
| 385 |
PMH3 AUSTRALIAN SCHIZOPHRENIC PATIENTS TREATED WITH RISPERIDONE LONG-ACTING INJECTION (RLAI): INTERIM RESULTS FROM THE E-STAR STUDY
|
Emmerson, B
|
|
2006
|
9 |
3 |
p. A64-A65
nvt p.
|
artikel
|
| 386 |
PMH15 BURDEN OF ILLNESS AMONG PATIENTS WITH ALZHEIMER'S DISEASE IN A COMMERCIALLY-INSURED POPULATION
|
Zhao, Y
|
|
2006
|
9 |
3 |
p. A68-A69
nvt p.
|
artikel
|
| 387 |
PMH14 BURDEN OF ILLNESS OF ALZHEIMER'S PATIENTS IN COMMERCIAL MANAGED CARE
|
Zhao, Y
|
|
2006
|
9 |
3 |
p. A68-
1 p.
|
artikel
|
| 388 |
PMH39 COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS
|
Obeidat, NA
|
|
2006
|
9 |
3 |
p. A76-
1 p.
|
artikel
|
| 389 |
PMH37 COMPARING ADHERENCE AND PERSISTENCE WITH ANTIPSYCHOTIC THERAPY AMONG PATIENTS WITH BIPOLAR DISORDER
|
Hassan, M
|
|
2006
|
9 |
3 |
p. A75-A76
nvt p.
|
artikel
|
| 390 |
PMH42 COMPLIANCE AND PERSISTENCE: A COMPARISON BETWEEN TYPICAL AND ATYPICAL ANTIPSYCHOTIC TREATMENT OF SCHIZOPHRENIA PATIENTS
|
Liu, GG
|
|
2006
|
9 |
3 |
p. A77-
1 p.
|
artikel
|
| 391 |
PMH10 COST AND EFFECTIVENESS OF SWITCHING FROM RISPERIDONE TO OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA
|
Thomas, NA
|
|
2006
|
9 |
3 |
p. A67-
1 p.
|
artikel
|
| 392 |
PMH9 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF ACUTE MANIA
|
Meletiche, DM
|
|
2006
|
9 |
3 |
p. A66-A67
nvt p.
|
artikel
|
| 393 |
PMH8 COST-EFFECTIVENESS OF VENLAFAXINE: A CANADIAN PERSPECTIVE
|
Sadri, H
|
|
2006
|
9 |
3 |
p. A66-
1 p.
|
artikel
|
| 394 |
PMH20 COST OF TREATMENT OF HYPERKINETIC DISORDER IN GERMANY
|
Wehmeier, PM
|
|
2006
|
9 |
3 |
p. A70-
1 p.
|
artikel
|
| 395 |
PMH1 CRITERIA FOR IDENTIFYING PATIENTS WITH DEMENTIA AND PREVALENCE ESTIMATES OF DEMENTIA AMONG INDIANA MEDICAID RECIPIENTS
|
Bharmal, M
|
|
2006
|
9 |
3 |
p. A64-
1 p.
|
artikel
|
| 396 |
PMH33 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS PRESCRIBED ANTIPSYCHOTIC (AP) MONOTHERAPY IN TEXAS MEDICAID
|
Harrington, P
|
|
2006
|
9 |
3 |
p. A74-
1 p.
|
artikel
|
| 397 |
PMH34 DETERMINANTS IN ANTIDEPRESSANT TREATMENT SELECTION FOLLOWING THE INTRODUCTION OF DULOXETINE
|
Robinson, RL
|
|
2006
|
9 |
3 |
p. A74-A75
nvt p.
|
artikel
|
| 398 |
PMH45 DURATION OF ANTIPSYCHOTIC SWITCHING PROCESS IN THE NATURALISTIC TREATMENT OF SCHIZOPHRENIA
|
Thomas, NA
|
|
2006
|
9 |
3 |
p. A78-
1 p.
|
artikel
|
| 399 |
PMH44 ECONOMIC CONSEQUENCES OF PATIENTS NOT ADHERING TO MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA
|
Sun, SX
|
|
2006
|
9 |
3 |
p. A77-A78
nvt p.
|
artikel
|
| 400 |
PMH30 EVALUATION OF SELECTIVE SEROTONIN REPUTAKE INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION
|
Sun, SX
|
|
2006
|
9 |
3 |
p. A73-
1 p.
|
artikel
|
| 401 |
PMH16 HEALTH CARE COSTS AND UTILIZATION PATTERNS OF INDIVIDUALS WITH GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED STATES
|
Liu, GG
|
|
2006
|
9 |
3 |
p. A69-
1 p.
|
artikel
|
| 402 |
PMH21 HEALTH CARE RESOURCE UTILIZATION AND COST OF BIPOLAR I DISORDER WITH AND WITHOUT PSYCHOTIC SYMPTOMS
|
Poston, S
|
|
2006
|
9 |
3 |
p. A70-
1 p.
|
artikel
|
| 403 |
PMH23 HEALTH CARE RESOURCE UTILIZATION PRE/POST RISPERIDONE LONG-ACTING INJECTABLE TREATMENT INITIATION IN A MANAGED CARE POPULATION
|
Poston, S
|
|
2006
|
9 |
3 |
p. A71-
1 p.
|
artikel
|
| 404 |
PMH46 HEALTH-RELATED QUALITY-OF-LIFE MEASURED BY EQ-5D IN PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE
|
Sobocki, P
|
|
2006
|
9 |
3 |
p. A78-
1 p.
|
artikel
|
| 405 |
PMH5 INCIDENT DIABETES ASSOCIATED WITH USE OF SECOND-GENERATION ANTIPSYCHOTIC (SGA) THERAPY:AN EVALUATION OF THE IMPACT OF DOSE AND TREATMENT INDICATION
|
Harrington, P
|
|
2006
|
9 |
3 |
p. A65-
1 p.
|
artikel
|
| 406 |
PMH24 INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS: EFFECTS ON THE TREATMENT FOR SCHIZOPHRENIA IN A MEDI-CAL POPULATION
|
Biagi, L Vicki
|
|
2006
|
9 |
3 |
p. A71-
1 p.
|
artikel
|
| 407 |
PMH25 LEARNING FROM NICE TECHNOLOGY ASSESSMENTS: A CASE STUDY OF ITS RECENT APPRAISAL OF ADHD TREATMENT STRATEGIES
|
Schiander, M
|
|
2006
|
9 |
3 |
p. A71-A72
nvt p.
|
artikel
|
| 408 |
PMH31 LIKELIHOOD OF EMPLOYMENT TERMINATION FOR EMPLOYEES WITH BIPOLAR DISORDER TREATED WITH DIFFERENT PSYCHOTROPIC MEDICATIONS
|
Rajagopalan, K
|
|
2006
|
9 |
3 |
p. A73-A74
nvt p.
|
artikel
|
| 409 |
PMH48 MEASUREMENT OF UTILITY LOSSES IN DEPRESSION
|
Mauskopf, J
|
|
2006
|
9 |
3 |
p. A79-
1 p.
|
artikel
|
| 410 |
PMH2 META-ANALYSIS OF ANTIDEPRESSANTTREATMENT EFFECTS IN PATIENTS AFTER STROKE
|
Chen, Y
|
|
2006
|
9 |
3 |
p. A64-
1 p.
|
artikel
|
| 411 |
PMH4 META-ANALYSIS OF SNRIS, SSRIS, AND TCAS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER USING REMISSION AS THE CLINICAL OUTCOME
|
Machado, M
|
|
2006
|
9 |
3 |
p. A65-
1 p.
|
artikel
|
| 412 |
PMH6 NEW-ONSET DIABETES MELLITUS ASSOCIATED WITH USE OF ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIC PATIENTS IN TAIWAN
|
Cheng, JS
|
|
2006
|
9 |
3 |
p. A65-A66
nvt p.
|
artikel
|
| 413 |
PMH41 PREDICTORS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
|
Thomas, NA
|
|
2006
|
9 |
3 |
p. A77-
1 p.
|
artikel
|
| 414 |
PMH43 RAMIFICATIONS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
|
Thomas, NA
|
|
2006
|
9 |
3 |
p. A77-
1 p.
|
artikel
|
| 415 |
PMH17 RESOURCE-USE AND COSTS ASSOCIATED WITH PATIENTS TREATED FOR DEPRESSION IN PRIMARY CARE
|
Sobocki, P
|
|
2006
|
9 |
3 |
p. A69-
1 p.
|
artikel
|
| 416 |
PMH26 REVIEW ON HEALTH OUTCOMES ASSOCIATED WITH DEPOT ANTIPSYCHOTIC AGENTS AND LONG-ACTING RISPERIDONE INJECTABLE (LARI) FOR TREATMENT OF SCHIZOPHRENIA
|
Shi, L
|
|
2006
|
9 |
3 |
p. A72-
1 p.
|
artikel
|
| 417 |
PMH28 SELECTION OF ATYPICAL ANTIPSYCHOTIC MONO-THERAPY FOR PATIENTS WITH BIPOLAR DISORDER: AN ANALYSIS OF A MEDICAID POPULATION
|
Oiu, Y
|
|
2006
|
9 |
3 |
p. A72-A73
nvt p.
|
artikel
|
| 418 |
PMH35 THE COST OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
|
Zhu, G
|
|
2006
|
9 |
3 |
p. A75-
1 p.
|
artikel
|
| 419 |
PMH27 THE IMPACT OF PRESCRIBING OFF-LABEL MOOD STABILIZERS FOR PATIENTS WITH SCHIZOPHRENIA
|
Chen, H
|
|
2006
|
9 |
3 |
p. A72-
1 p.
|
artikel
|
| 420 |
PMH47 THE MISSION IS REMISSION–HEALTH ECONOMIC CONSEQUENCES OF ACHIEVING REMISSION WITH ANTIDEPRESSANT TREATMENT FOR DEPRESSION
|
Sobocki, P
|
|
2006
|
9 |
3 |
p. A78-A79
nvt p.
|
artikel
|
| 421 |
PMH36 VARIATIONS IN THE OPERATIONAL DEFINITION OF MOOD DISORDERS IN RETROSPECTIVE CLAIMS DATABASE STUDIES
|
Montejano, LB
|
|
2006
|
9 |
3 |
p. A75-
1 p.
|
artikel
|
| 422 |
PMS3 COMPARISON OF HOSPITAL COST WITH DRG REIMBURSEMENT RATE IN PATIENTS WITH PERITROCHANTERIC FRACTURE ACCORDING TO SURGICAL METHODS
|
Fodor, B
|
|
2006
|
9 |
3 |
p. A161-
1 p.
|
artikel
|
| 423 |
PMS1 HEALTH TECHNOLOGY ASSESSMENT: EXTRACORPOREAL SHOCKWAVE THERAPY (ESWT) FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS
|
Seybold, P
|
|
2006
|
9 |
3 |
p. A160-A161
nvt p.
|
artikel
|
| 424 |
PMS2 THE COST-EFFECTIVENESS OF EXTRACORPOREAL SHOCK WAVE THERAPY FOR THE TREATMENT OF CHRONIC PLANTAR FASCIITIS
|
Marangos, PJ
|
|
2006
|
9 |
3 |
p. A161-
1 p.
|
artikel
|
| 425 |
PNL29 A REVIEW OF THE VALIDITY AND RELIABILITY OF THE PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-39)
|
Stafkey-Mailey, DR
|
|
2006
|
9 |
3 |
p. A88-
1 p.
|
artikel
|
| 426 |
PNL5 ASSESSING ABSOLUTE REDUCTIONS IN CLINICAL EFFECT: A MODEL FOR COMPARING THE COST-EFFECTIVENESS OF DISEASE MODIFYING DRUGS (DMDS) UTILIZED IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)
|
Goldberg, LD
|
|
2006
|
9 |
3 |
p. A80-A81
nvt p.
|
artikel
|
| 427 |
PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORYTHERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA
|
Bell, CF
|
|
2006
|
9 |
3 |
p. A81-A82
nvt p.
|
artikel
|
| 428 |
PNL1 CLINICAL EFFECTIVENESS AND HEALTH OUTCOMES OF DISEASE MODIFYING TREATMENT (DMT) THAT DELAYS DISABILITY PROGRESSION IN RELAPSING/REMITTING-ONSET MULTIPLE SCLEROSIS: NOVA SCOTIA “REAL WORLD” EVIDENCE
|
Brown, MG
|
|
2006
|
9 |
3 |
p. A79-
1 p.
|
artikel
|
| 429 |
PNL11 COMPARING APPLES WITH WHAT: DIFFERENT INPUTS AND ASSUMPTIONS PRODUCE DIFFERENT CONCLUSIONS IN MS ECONOMIC MODELS
|
Noyes, K
|
|
2006
|
9 |
3 |
p. A82-A83
nvt p.
|
artikel
|
| 430 |
PNL4 COMPARING THE RELATIVE COST-EFFECTIVENESS OF ORAL PROPHYLACTIC MEDICATION VS. BOTULINUM TOXIN TYPE A (BOTOX®) IN THE MANAGEMENT OF MIGRAINE HEADACHE: A MODEL EVALUATING THE CLINICAL AND ECONOMIC IMPACT OF CURRENT TREATMENT OPTIONS
|
Goldberg, LD
|
|
2006
|
9 |
3 |
p. A80-
1 p.
|
artikel
|
| 431 |
PNL30 COMPARISON OF HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN MULTIPLE SCLEROSIS: A REVIEW
|
Pawar, VS
|
|
2006
|
9 |
3 |
p. A88-A89
nvt p.
|
artikel
|
| 432 |
PNL23 CONTROLLING SELECTION BIAS ON CONTINUOUS VARIABLES
|
Baser, O
|
|
2006
|
9 |
3 |
p. A86-
1 p.
|
artikel
|
| 433 |
PNL12 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN: RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL
|
Weis, K
|
|
2006
|
9 |
3 |
p. A83-
1 p.
|
artikel
|
| 434 |
PNL10 COST-EFFECTIVENESS OF MS DISEASE MODIFYING AGENTS: A MARKOV ANDVALUE OF INFORMATION ANALYSIS
|
Lundy, J
|
|
2006
|
9 |
3 |
p. A82-
1 p.
|
artikel
|
| 435 |
PNL14 COST-EFFECTIVENESS OF PREGABALIN AS ADJUNCT TO STANDARD THERAPY IN PATIENTS WITH REFRACTORY PARTIAL EPILEPSY
|
Vera-Llonch, M
|
|
2006
|
9 |
3 |
p. A83-A84
nvt p.
|
artikel
|
| 436 |
PNL9 COST-EFFECTIVENESS OFTOPIRAMATE FOR MIGRAINE PREVENTION: A MANAGED CARE PERSPECTIVE
|
Brown, J
|
|
2006
|
9 |
3 |
p. A82-
1 p.
|
artikel
|
| 437 |
PNL7 COST-EFFICACY ANALYSIS OF MULTIPLE SCLEROSIS THERAPIES: ASSESSING THE IMPACT OF NEUTRALIZING ANTIBODIES
|
Munschauer, F
|
|
2006
|
9 |
3 |
p. A81-
1 p.
|
artikel
|
| 438 |
PNL15 COST-OF-ILLNESS FOR ADULTS WITH PARTIAL EPILEPSY IN SWEDEN
|
Mork, AC
|
|
2006
|
9 |
3 |
p. A84-
1 p.
|
artikel
|
| 439 |
PNL18 DIRECT COST BURDEN OF MIGRAINE AMONG MEMBERS OF US EMPLOYER GROUPS
|
Hawkins, K
|
|
2006
|
9 |
3 |
p. A85-
1 p.
|
artikel
|
| 440 |
PNL16 ECONOMIC BURDEN OF PAIN DUE TO MULTIPLE SCLEROSIS IN CANADA
|
Piwko, C
|
|
2006
|
9 |
3 |
p. A84-
1 p.
|
artikel
|
| 441 |
PNL19 ECONOMIC BURDEN OF RESTLESS LEGS SYNDROME INA PRIVATELY-INSURED POPULATION
|
Curtice, TG
|
|
2006
|
9 |
3 |
p. A85-
1 p.
|
artikel
|
| 442 |
PNL17 ECONOMIC COSTS OF CHRONIC PRIMARY INSOMNIA IN THE UNITED STATES
|
Thompson, D
|
|
2006
|
9 |
3 |
p. A84-A85
nvt p.
|
artikel
|
| 443 |
PNL22 ESTIMATING THE COST OF NURSING HOME CARE FOR PATIENTS WITH PARKINSON'S DISEASE USING RETROSPECTIVE DATABASE ANALYSIS
|
Anderson, K
|
|
2006
|
9 |
3 |
p. A86-
1 p.
|
artikel
|
| 444 |
PNL32 EVALUATION OF THE IMPACT OF AN EMPLOYEE WORKSITE DISEASE MANAGEMENT PROGRAM FOR MIGRAINEURS ON WORK PRODUCTIVITY
|
Borok, GM
|
|
2006
|
9 |
3 |
p. A89-
1 p.
|
artikel
|
| 445 |
PNL6 EXAMINATION OF THE COST-EFFECTIVENESS OF DOPAMINE AGONISTS FORTHETREATMENT OF RESTLESS LEGS SYNDROME
|
Beard, AJ
|
|
2006
|
9 |
3 |
p. A81-
1 p.
|
artikel
|
| 446 |
PNL26 EXTENDING MATCHING ESTIMATORS OF CAUSAL EFFECTS TO CONSIDER UNOBSERVED VARIABLE BIAS: AN APPLICATION OF SENSITIVITY ANALYSIS
|
Devine, JW
|
|
2006
|
9 |
3 |
p. A87-
1 p.
|
artikel
|
| 447 |
PNL25 FAILURE OF REGRESSION ADJUSTMENT AGAINST PROPENSITY SCORE MATCHING
|
Baser, O
|
|
2006
|
9 |
3 |
p. A87-
1 p.
|
artikel
|
| 448 |
PNL20 HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE SCLEROSIS IN A COMMERCIAL MANAGED CARE ENVIRONMENT
|
Prescott, J
|
|
2006
|
9 |
3 |
p. A85-A86
nvt p.
|
artikel
|
| 449 |
PNL31 HEALTHCARE UTILIZATION AND PATIENT SATISFACTION WITH TRIPTAN TREATMENT IN MIGRAINEURS
|
Ambegaonkar, A
|
|
2006
|
9 |
3 |
p. A89-
1 p.
|
artikel
|
| 450 |
PNL3 HOSPITAL LENGTH OF STAY ASSOCIATED WITH ANTICONVULSANT UTILIZATION BY PATIENTS WITH SEIZURE DISORDERS IN THE U.S.
|
Blanchette, CM
|
|
2006
|
9 |
3 |
p. A80-
1 p.
|
artikel
|
| 451 |
PNL21 PATTERNS OF TOPIRAMATE UTILIZATION AMONG MEDICAID PATIENTS: DIAGNOSIS, COMORBIDITIES AND REAL-WORLD DOSING
|
Poston, S
|
|
2006
|
9 |
3 |
p. A86-
1 p.
|
artikel
|
| 452 |
PNL2 RESTLESS LEGS SYNDROME: IDENTIFICATION OF TREATED PATIENTS IN A LARGE CLAIMS DATABASE
|
Montejano, LB
|
|
2006
|
9 |
3 |
p. A79-A80
nvt p.
|
artikel
|
| 453 |
PNL28 STUDYING DISCONTINUATION, SWITCHING, AND AUGMENTATION USING COMPETING RISK METHODS
|
Gause, D
|
|
2006
|
9 |
3 |
p. A88-
1 p.
|
artikel
|
| 454 |
PNL27 THE EFFECT OF ADHERENCE TO ALZHEIMER'S DISEASE TREATMENT ON HEALTH CARE COSTS IN MANAGED CARE
|
Harada, ASM
|
|
2006
|
9 |
3 |
p. A87-A88
nvt p.
|
artikel
|
| 455 |
PNL24 THE ESTIMATION POWER OF ALTERNATIVE COMORBIDITY INDEXES
|
Baser, O
|
|
2006
|
9 |
3 |
p. A87-
1 p.
|
artikel
|
| 456 |
PNL13 WINNERS AND LOSERS: PATTERNS IN ECONOMIC EVALUATIONS OF ANTI-EPILEPTIC DRUGS
|
Mladsi, D
|
|
2006
|
9 |
3 |
p. A83-
1 p.
|
artikel
|
| 457 |
POB1 ASSOCIATION BETWEEN BMI AND HEALTH CARE EXPENDITURES USING THE 2002 MEDICAL EXPENDITURE PANEL SURVEY
|
Valderrama, A
|
|
2006
|
9 |
3 |
p. A89-A90
nvt p.
|
artikel
|
| 458 |
POB2 COSTS OF PREMATURE DEATH ATTRIBUTED TO OBESITY IN SPAIN
|
Echevarria, A
|
|
2006
|
9 |
3 |
p. A90-
1 p.
|
artikel
|
| 459 |
POB3 COST-UTILITY ANALYSIS OF RIMONABANT IN THE TREATMENT OF OBESITY
|
Hampp, C
|
|
2006
|
9 |
3 |
p. A90-
1 p.
|
artikel
|
| 460 |
POB9 EFFECT OF RIMONABANT ON QUALITY OF LIFE IN OVERWEIGHT/OBESE PATIENTS
|
Kolotkin, RL
|
|
2006
|
9 |
3 |
p. A92-
1 p.
|
artikel
|
| 461 |
POB8 IMPACT OF ABDOMINAL OBESITY ON QUALITY OF LIFE
|
Kolotkin, RL
|
|
2006
|
9 |
3 |
p. A91-A92
nvt p.
|
artikel
|
| 462 |
POB7 OBESITY AND QUALITY OF LIFE IN THE UNITED STATES: 2000-2002
|
Wu, E
|
|
2006
|
9 |
3 |
p. A91-
1 p.
|
artikel
|
| 463 |
POB6 SELF-IMAGE SCALE: A PRAGMATIC EVALUATION
|
Taieb, C
|
|
2006
|
9 |
3 |
p. A91-
1 p.
|
artikel
|
| 464 |
POB5 THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED QUALITY OF LIFE AMONG US ADULTS
|
Olesen, AC
|
|
2006
|
9 |
3 |
p. A91-
1 p.
|
artikel
|
| 465 |
POB4 USE OF GROWTH CURVE ANALYSES FOR DISCRETE EVENT SIMULATION: A CASE STUDY OF POOLED CLINICAL TRIALS OF THE EFFECTS OF RIMONABANT ON CARDIOMETABOLIC RISK FACTORS IN OBESE PATIENTS
|
Caro, JJ
|
|
2006
|
9 |
3 |
p. A90-A91
nvt p.
|
artikel
|
| 466 |
POS3 BUDGET IMPACT ANALYSIS OF BISPHOSPHONATES FOR FRACTURES IN POSTMENOPAUSAL WOMEN
|
Nishida, LM
|
|
2006
|
9 |
3 |
p. A162-
1 p.
|
artikel
|
| 467 |
POS7 CHANGES IN THE IMPAIRED ABILITYTO WORK IN PATIENTS UNDER 60 WITH MEDIAL FEMORAL NECK FRACTURE DURING 3 YEARS FOLLOW UP
|
Sebestyén, A
|
|
2006
|
9 |
3 |
p. A163-A164
nvt p.
|
artikel
|
| 468 |
POS4 COMPARATIVE ANALYSIS OF HEALTH INSURANCE COST OF MEDIAL FEMORAL NECK FRACTURES WITH AND WITHOUT COMPLICATIONS ON A 2 YEARS FOLLOW UP
|
Sebestyén, A
|
|
2006
|
9 |
3 |
p. A162-A163
nvt p.
|
artikel
|
| 469 |
POS13 COMPLIANCE, DISCONTINUATION, AND SWITCHING OF OSTEOPOROSIS TREATMENT IN LOUISIANA MEDICAID POST-MENOPAUSAL WOMEN
|
Trivedi, DN
|
|
2006
|
9 |
3 |
p. A165-A166
nvt p.
|
artikel
|
| 470 |
POS6 COST OF FALLS IN LONG-TERM CARE FACILITIES (LTCFS)
|
Carroll, NV
|
|
2006
|
9 |
3 |
p. A163-
1 p.
|
artikel
|
| 471 |
POS14 HOME AUTOMATED TELEMANAGEMENT IN POST-HIP FRACTURE REHABILITATION
|
Finkelstein, J
|
|
2006
|
9 |
3 |
p. A166-
1 p.
|
artikel
|
| 472 |
POS1 ONE-AND TWO-YEAR PERSISTENT USE OF BISPHOSPHONATES REDUCES THE RISK OF OSTEOPOROTIC FRACTURES IN DAILY PRACTICE
|
Goettsch, WG
|
|
2006
|
9 |
3 |
p. A161-A162
nvt p.
|
artikel
|
| 473 |
POS12 PATIENT ADHERENCE WITH BISPHOSPHONATES AT 6 MONTHS: A RETROSPECTIVE COHORT STUDY
|
Borisov, N
|
|
2006
|
9 |
3 |
p. A165-
1 p.
|
artikel
|
| 474 |
POS8 PRICE AND UTILIZATION OF OSTEOPOROSIS MEDICATIONS IN U.S. MEDICAID PROGRAMS
|
Knight, D
|
|
2006
|
9 |
3 |
p. A164-
1 p.
|
artikel
|
| 475 |
POS5 THE COST-EFFECTIVENESS OF IBANDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN THE US
|
Earnshaw, SR
|
|
2006
|
9 |
3 |
p. A163-
1 p.
|
artikel
|
| 476 |
POS2 THE EFFECT OF RISK FACTORS ON MORTALITY AFTER PRIMARYTREATMENT OF FEMORAL NECK FRACTURE AT DIFFERENT TIME PERIODS IN HUNGARY
|
Sebestyén, A
|
|
2006
|
9 |
3 |
p. A162-
1 p.
|
artikel
|
| 477 |
POS11 THE USE OF INDIVIDUAL RISKS RATHER THAN POPULATION AVERAGES IN COST-EFFECTIVENESS MODELING
|
Van Staa, TP
|
|
2006
|
9 |
3 |
p. A165-
1 p.
|
artikel
|
| 478 |
POS10 TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PATIENTS WITH PAGET'S DISEASE TREATED WITH RISENDRONATE
|
Doyle, J
|
|
2006
|
9 |
3 |
p. A164-A165
nvt p.
|
artikel
|
| 479 |
POS9 TRENDS IN THE CLINICAL MANAGEMENT OF FRAGILE FRACTURE BEFORE AND AFTERTHE NEW HEDIS OSTEOPOROSIS MANAGEMENT MEASURE IN A MEDICARE POPULATION
|
Foster, S
|
|
2006
|
9 |
3 |
p. A164-
1 p.
|
artikel
|
| 480 |
POT3 COST OF HOSPITALIZATIONS FOR ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS PRE-AND POST-REPEAL OF THE UNIVERSAL HELMET LAW IN FLORIDA
|
O'Brien, JA
|
|
2006
|
9 |
3 |
p. A166-A167
nvt p.
|
artikel
|
| 481 |
POT2 FATIGUE IN THE U.S. WORKFORCE: PREVALENCE AND COST OF LOST PRODUCTIVE WORK TIME
|
Ricci, J
|
|
2006
|
9 |
3 |
p. A166-
1 p.
|
artikel
|
| 482 |
POT1 INCIDENCE AND ECONOMIC IMPACT ANALYSIS OF HYPONATREMIA IN HOSPITALIZED PATIENTS
|
Long, J
|
|
2006
|
9 |
3 |
p. A166-
1 p.
|
artikel
|
| 483 |
PPN5 ADVANCES IN PAIN MEASUREMENT: ITEM RESPONSE THEORY (IRT) BASED METHODS AND THE PAIN IMPACT QUESTIONNAIRE (PIQ-6)
|
Becker, J
|
|
2006
|
9 |
3 |
p. A168-
1 p.
|
artikel
|
| 484 |
PPN2 IMPACT OF BACK PAIN ON ABSENTEEISM, PRODUCTIVITY LOSS, AND DIRECT HEALTH CARE COSTS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
|
Parthan, A
|
|
2006
|
9 |
3 |
p. A167-
1 p.
|
artikel
|
| 485 |
PPN1 OPIOID ASSOCIATED ERECTILE DISFUNCTION IN CHRONIC PAIN PATIENTS
|
Marsh, B
|
|
2006
|
9 |
3 |
p. A167-
1 p.
|
artikel
|
| 486 |
PPN4 PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO PATIENT CONTROLLED ANALGESIA
|
Nuyts, G
|
|
2006
|
9 |
3 |
p. A168-
1 p.
|
artikel
|
| 487 |
PPN3 THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS: COST EFFECTS IN THE CALIFORNIA WORKERS' COMPENSATION SYSTEM
|
Gitlin, M
|
|
2006
|
9 |
3 |
p. A167-A168
nvt p.
|
artikel
|
| 488 |
PR1 A BAYESIAN ESTIMATION OF AN AVERAGE SF-6D PREFERENCE BASED SCORE FROM COMMONLY REPORTED SF-12 STATISTICS
|
Hanmer, J
|
|
2006
|
9 |
3 |
p. A5-
1 p.
|
artikel
|
| 489 |
PR4 CONVERTING THE SCORES OF A CLINICAL INSTRUMENT FOR MEASURING PAIN TO A PREFERENCE BASED ONE
|
Iskedjian, M
|
|
2006
|
9 |
3 |
p. A6-
1 p.
|
artikel
|
| 490 |
PRO3 EVALUATION OF A PROGRAM TO IMPROVE ADHERENCE WITH PEGYLATED INTERFERON THERAPY: A PROPENSITY SCORE MATCHED RETROSPECTIVE COHORT ANALYSIS
|
Hussein, M
|
|
2006
|
9 |
3 |
p. A169-
1 p.
|
artikel
|
| 491 |
PRO5 PHYSICIAN IMPRESSIONSAND USES OF PATIENT-REPORTED OUTCOMES DATA
|
Kerney, D
|
|
2006
|
9 |
3 |
p. A170-
1 p.
|
artikel
|
| 492 |
PRO4 PREVALENCE OF MEDICATION COMPLIANCE AND PERSISTENCY WITH SPECIALTY MEDICATIONS IN MANAGED CARE POPULATION
|
Fuldeore, M
|
|
2006
|
9 |
3 |
p. A169-
1 p.
|
artikel
|
| 493 |
PRO1 RESULTS OF ALTERNATIVE DEFINITIONS FOR STATIN REFILL COMPIANCE, PERSISTENCE AND GAPS IN A RETROSPECTIVE DATABASE ANALYSIS
|
Kochevar, JJ
|
|
2006
|
9 |
3 |
p. A168-A169
nvt p.
|
artikel
|
| 494 |
PRO2 SELF-REPORTED HEALTH STATUS PREDICTORS OF MEDICATION ADHERENCE IN OLDER ADULTS WITH CHRONIC DISEASES
|
Balkrishnan, R
|
|
2006
|
9 |
3 |
p. A169-
1 p.
|
artikel
|
| 495 |
PR2 QUANTIFYING PATIENTS' RISK-BENEFIT TRADEOFF PREFERENCES: A CONCEPTUAL AND EMPIRICAL COMPARISON OF METHODS
|
Johnson, FR
|
|
2006
|
9 |
3 |
p. A5-
1 p.
|
artikel
|
| 496 |
PR3 RACIAL DIFFERENCES IN PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE ASSESSMENT
|
Fu, AZ
|
|
2006
|
9 |
3 |
p. A5-A6
nvt p.
|
artikel
|
| 497 |
PR7 RISK INDICATORS FOR SELF-REPORTED JOINT PAIN AND MOTION LIMITATION OUTCOMES IN HEMOPHILIA PATIENTS-THE HEMOPHILIA COST AND IMPACT OF DISEASE STUDY-PART V
|
Wu, J
|
|
2006
|
9 |
3 |
p. A12-
1 p.
|
artikel
|
| 498 |
PRS3 COMBINATION THERAPY [LONG ACTING BETA AGONISTS (LABA) PLUS INHALED CORTICOSTEROIDS] VERSUS LABA ALONE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN ECONOMIC ANALYSIS
|
Mayers, I
|
|
2006
|
9 |
3 |
p. A93-
1 p.
|
artikel
|
| 499 |
PRS9 EVALUATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS INITIATING AN INHALED CORTICOSTEROID OR AN ANTICHOLINERGIC INA MANAGED CARE POPULATION
|
Shetty, SS
|
|
2006
|
9 |
3 |
p. A94-A95
nvt p.
|
artikel
|
| 500 |
PRS2 EVALUATION OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG COPD PATIENTS USING INHALED CORTICOSTEROIDS ORANTICHOLINERGIC AGENTS IN A MANAGED CARE POPULATION
|
Shetty, SS
|
|
2006
|
9 |
3 |
p. A92-A93
nvt p.
|
artikel
|
| 501 |
PRS4 LIFETIME COSTS AND IMPACT ON LIFE EXPECTANCY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE U.S.: PROJECTIONS FROM A DECISION-ANALYTIC MODEL
|
Miller, JD
|
|
2006
|
9 |
3 |
p. A93-
1 p.
|
artikel
|
| 502 |
PRS5 RESOURCE USE AND COST OF HEALTHCARE SERVICES AMONG PATIENTS NEWLY DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS: EVIDENCE FROM A LARGE STATE MEDICAID PROGRAM
|
Boulanger, L
|
|
2006
|
9 |
3 |
p. A93-A94
nvt p.
|
artikel
|
| 503 |
PRS1 SURVIVAL AMONG COPD PATIENTS USING FLUTICASONE/SALMETEROL IN COMBINATION VERSUS OTHER INHALED STEROIDS AND BRONCHDIALATORS ALONE
|
Mapel, DW
|
|
2006
|
9 |
3 |
p. A92-
1 p.
|
artikel
|
| 504 |
PRS8 THE COST-EFFECTIVENESS OF PALIVIZUMAB IN AUSTRIA
|
Resch, B
|
|
2006
|
9 |
3 |
p. A94-
1 p.
|
artikel
|
| 505 |
PRS6 TOBACCO SMOKING AND DIRECT COSTS OF TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS
|
Targowski, T
|
|
2006
|
9 |
3 |
p. A94-
1 p.
|
artikel
|
| 506 |
PRS7 TREATING DOCTOR AND DIRECT COSTS OF HOSPITALIZATION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS
|
Jahnz-Rozyk, K
|
|
2006
|
9 |
3 |
p. A94-
1 p.
|
artikel
|
| 507 |
PR8 THE IMPACT OF ABNORMAL UTERINE BLEEDING ON HEALTH-RELATED QUALITY OF LIFE: A META-ANALYSIS
|
Liu, Z
|
|
2006
|
9 |
3 |
p. A12-
1 p.
|
artikel
|
| 508 |
PR5 VALIDATION OF THE HYPERPIGMENTATION TREATMENT SATISFACTION QUESTIONNAIRE (HPTSQ)
|
Colman, S
|
|
2006
|
9 |
3 |
p. A11-
1 p.
|
artikel
|
| 509 |
PR6 VALIDATION OF THE WORK PRODUCTIVITY QUESTIONNAIRE: RESULTS OF THE MATRIX STUDY
|
Talati, AR
|
|
2006
|
9 |
3 |
p. A11-A12
nvt p.
|
artikel
|
| 510 |
PSK3 “HEALTH BENEFIT LIMITS” LIMIT TREATMENT OF PSORIASIS AND OTHER DERMATOLOGICAL CONDITIONS
|
Venkat, A
|
|
2006
|
9 |
3 |
p. A171-
1 p.
|
artikel
|
| 511 |
PSK4 MEDICATION-RELATED FACTORS AFFECTING HEALTH CARE OUTCOMES AND COSTS IN PATIENTS WITH PSORIASIS AND ACNE IN THE UNITED STATES
|
Kulkarni, AS
|
|
2006
|
9 |
3 |
p. A171-
1 p.
|
artikel
|
| 512 |
PSK1 PATTERNS FOR PHOTOTHERAPY USE IN TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
|
Kulkarni, AS
|
|
2006
|
9 |
3 |
p. A170-
1 p.
|
artikel
|
| 513 |
PSK2 PHYSICIAN AND PATIENT RELATED DETERMINANTS OF PRESCRIBING TOPICAL CALCINEURIN INHIBITORS FOR PATIENTS WITH ATOPIC DERMATITIS: ANALYSIS OF U.S. NATIONAL OUTPATIENTVISIT DATA
|
Bhosle, MJ
|
|
2006
|
9 |
3 |
p. A170-
1 p.
|
artikel
|
| 514 |
PSK5 TREATMENT PATTERNS IN PATIENTS WITH SEVERE PSORIASIS
|
Kulkarni, AS
|
|
2006
|
9 |
3 |
p. A171-
1 p.
|
artikel
|
| 515 |
PSK6 USING MEDIATION MODELS TO ASSESS THE INCREMENTAL VALUE OF QUALITY OF LIFE QUESTIONNAIRES: DLQI IN PSORIASIS
|
Bala, M
|
|
2006
|
9 |
3 |
p. A171-A172
nvt p.
|
artikel
|
| 516 |
PSM2 EFFECT OF SMOKING ON PERCEIVED HEALTH STATUS
|
Yaffe, K
|
|
2006
|
9 |
3 |
p. A172-A173
nvt p.
|
artikel
|
| 517 |
PSM1 POTENTIAL BENEFITS OF SMOKING CESSATION TREATMENT COVERAGE AT THE WORKPLACE
|
Halpern, MT
|
|
2006
|
9 |
3 |
p. A172-
1 p.
|
artikel
|
| 518 |
PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA)
|
Goeree, RA
|
|
2006
|
9 |
3 |
p. A173-
1 p.
|
artikel
|
| 519 |
PSU2 THE SHORT TERM COST-EFFECTIVENESS OF 45 SURGICAL INTERVENTIONS IN THE UK
|
Wechowski, JG
|
|
2006
|
9 |
3 |
p. A173-
1 p.
|
artikel
|
| 520 |
PUK2 ASSOCIATION BETWEEN IN-HOSPITAL FALLS, COMORBIDITIES, AND DRUG USE IN ADULT CHRONIC KIDNEY DISEASE PATIENTS: A CASE-CONTROL STUDY
|
Angalakuditi, M
|
|
2006
|
9 |
3 |
p. A95-
1 p.
|
artikel
|
| 521 |
PUK3 ECONOMIC IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY-INSURED PERSONS ≥65 YEARS OF AGE WITH OVERACTIVE BLADDER
|
Joyce, AT
|
|
2006
|
9 |
3 |
p. A95-A96
nvt p.
|
artikel
|
| 522 |
PUK4 ELEVATED INTACT PARATHYROID HORMONE LEVELSAND HEALTH CARE COSTS AND UTILIZATION: RETROSPECTIVE COHORT OF PATIENTS WITH CHRONIC KIDNEY DISEASE
|
Johnson, ES
|
|
2006
|
9 |
3 |
p. A96-
1 p.
|
artikel
|
| 523 |
PUK5 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS IN ANEMIC PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
|
Mody, S
|
|
2006
|
9 |
3 |
p. A96-
1 p.
|
artikel
|
| 524 |
PUK9 ESTIMATING A PREFERENCE-BASED INDEX FROM A CONDITION SPECIFIC MEASURE-THE KING'S HEALTH QUESTIONNAIRE
|
Reeves, P
|
|
2006
|
9 |
3 |
p. A97-A98
nvt p.
|
artikel
|
| 525 |
PUK11 ESTIMATING A PREFERENCE-BASED SINGLE INDEX FROM THE OVERACTIVE BLADDER QUESTIONNAIRE
|
Brazier, JE
|
|
2006
|
9 |
3 |
p. A98-
1 p.
|
artikel
|
| 526 |
PUK6 EVALUATING THE OUTCOME AND COST ASSOCIATED WITH ATAMSULOSIN REAUTHORIZATION PROGRAM
|
Binkley, JR
|
|
2006
|
9 |
3 |
p. A96-A97
nvt p.
|
artikel
|
| 527 |
PUK7 FACTORS INFLUENCING EARLY NEPHROLOGY CARE PRIOR TO HEMODIALYSIS INITIATION AMONG ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE
|
Zhao, Y
|
|
2006
|
9 |
3 |
p. A97-
1 p.
|
artikel
|
| 528 |
PUK13 GENERIC VS. DISEASE-SPECIFIC SATISFACTION MEASURES: SELECTING A SATISFACTION MEASURE FOR OVERACTIVE BLADDER STUDIES
|
Evans, C
|
|
2006
|
9 |
3 |
p. A99-
1 p.
|
artikel
|
| 529 |
PUK8 ONE SOLUTION TO THREE PROBLEMS
|
Baser, O
|
|
2006
|
9 |
3 |
p. A97-
1 p.
|
artikel
|
| 530 |
PUK1 PREVALENCE OF NEUROGENIC BLADDER IN PATIENTS WITH VARIOUS NEUROLOGIC DISORDERS IN THE UNITED STATES
|
Shenolikar, R
|
|
2006
|
9 |
3 |
p. A95-
1 p.
|
artikel
|
| 531 |
PUK10 PSYCHOMETRIC PROPERTIES OF THE KING'S HEALTH QUESTIONNAIRES SYSTEMATIC CRITICAL APPRISAL OF THE LITERATURE
|
Lee, LJ
|
|
2006
|
9 |
3 |
p. A98-
1 p.
|
artikel
|
| 532 |
PUK12 QUALITY OF LIFE IN YOUNG MEN AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: RESULTS FROM THE CAPSURE REGISTRY
|
Wright, JL
|
|
2006
|
9 |
3 |
p. A98-A99
nvt p.
|
artikel
|
| 533 |
PUK14 WORK PRODUCTIVITY IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM THE MATRIX STUDY
|
Talati, AR
|
|
2006
|
9 |
3 |
p. A99-
1 p.
|
artikel
|
| 534 |
RS4 AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH CARE UTILIZATION AND USE OF SALMETEROL AMONG SUBJECTS WITH ASTHMA
|
Wang, MT
|
|
2006
|
9 |
3 |
p. A7-
1 p.
|
artikel
|
| 535 |
RS2 COST-EFFECTIVENESS OFTELITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
|
McGarry, LJ
|
|
2006
|
9 |
3 |
p. A6-
1 p.
|
artikel
|
| 536 |
RS3 LONG TERM SURVIVAL AS A FUNCTION OF AIRWAY OBSTRUCTION (FEV,) IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A POPULATION BASED RECORD LINKAGE STUDY IN A LARGE UK POPULATION
|
Woehl, A
|
|
2006
|
9 |
3 |
p. A7-
1 p.
|
artikel
|
| 537 |
RS1 TRENDS IN MEDICATION PRESCRIBING FOR CHILDREN WITH SLEEP DISORDERS IN US OUTPATIENT SETTINGS
|
Rasu, RS
|
|
2006
|
9 |
3 |
p. A6-
1 p.
|
artikel
|
| 538 |
Substantial Returns to Health-Care Spending: But Do We Spend Too Little or Too Much?
|
Buxton, Martin J.
|
|
2006
|
9 |
3 |
p. 144-145
2 p.
|
artikel
|
| 539 |
Substantial Returns to Health-Care Spending: But Do We Spend Too Little or Too Much?
|
Buxton, Martin J.
|
|
2006
|
9 |
3 |
p. 144-145
|
artikel
|
| 540 |
The Future of Health Economic Modeling: Have We Gone Too Far or Not Far Enough?
|
Fendrick, A. Mark
|
|
2006
|
9 |
3 |
p. 179-180
2 p.
|
artikel
|
| 541 |
The Future of Health Economic Modeling: Have We Gone Too Far or Not Far Enough?
|
Fendrick, A. Mark
|
|
2006
|
9 |
3 |
p. 179-180
|
artikel
|
| 542 |
The Return on Investment in Health Care: From 1980 to 2000
|
Luce, Bryan R.
|
|
2006
|
9 |
3 |
p. 146-156
11 p.
|
artikel
|
| 543 |
The Return on Investment in Health Care: From 1980 to 2000
|
Luce, Bryan R.
|
|
2006
|
9 |
3 |
p. 146-156
|
artikel
|
| 544 |
UR2 ECONOMIC BURDEN OF UNTREATED ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) PATIENTS: AN EMPLOYER'S PERSPECTIVE
|
Moyneur, É
|
|
2006
|
9 |
3 |
p. A17-
1 p.
|
artikel
|
| 545 |
UR3 FACTORS ASSOCIATED WITH CARE SEEKING FOR OVERACTIVE BLADDER SYMPTOMS
|
Nichol, MB
|
|
2006
|
9 |
3 |
p. A17-
1 p.
|
artikel
|
| 546 |
UR4 THE COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES FORABNORMAL UTERINE BLEEDING
|
Trussell, J
|
|
2006
|
9 |
3 |
p. A17-A18
nvt p.
|
artikel
|
| 547 |
UR1 THE ECONOMIC IMPACT OF EPOETIN ALFA (EPO) THERAPY ON DELAYING TIME TO DIALYSIS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)
|
Lefebvre, P
|
|
2006
|
9 |
3 |
p. A16-A17
nvt p.
|
artikel
|
| 548 |
What Decision-Makers Want and What They Have Been Getting
|
McGregor, Maurice
|
|
2006
|
9 |
3 |
p. 181-185
5 p.
|
artikel
|
| 549 |
What Decision-Makers Want and What They Have Been Getting
|
McGregor, Maurice
|
|
2006
|
9 |
3 |
p. 181-185
|
artikel
|
| 550 |
Where's the Value in Health Care?
|
Hay, Joel W.
|
|
2006
|
9 |
3 |
p. 141-143
3 p.
|
artikel
|
| 551 |
Where’s the Value in Health Care?
|
Hay, Joel W.
|
|
2006
|
9 |
3 |
p. 141-143
|
artikel
|
Tijdschrift beschrijving